




**IFCC-WorldLab EuroMedLab
Berlin 2011**
15-19 May

FIT FOR FUTURE - HELP HEALING THE WORLD

21st International Congress of Clinical Chemistry and Laboratory Medicine

19th IFCC-EFCC European Congress of Clinical Chemistry and Laboratory Medicine

8th Annual Meeting of the German Society of Clinical Chemistry and Laboratory Medicine

Berlin, Germany

ICC Berlin - Internationales Congress Centrum

15 - 19 May 2011

FINAL PROGRAM

Under the Auspices of:



Asian and Pacific Federation of Clinical Biochemistry



Clinical and Laboratory Standards Institute



World Association of Societies of Pathology and Laboratory Medicine



**Bundesministerium
für Bildung
und Forschung**

Bundesministerium für Bildung und Forschung

SUNDAY 15 MAY

17.30 - 19.30

HALL 1

OPENING CEREMONY

MONDAY 16 MAY

9:00-11:00 SYMPOSIUM 1 HALL 1

BIOMARKERS FOR THE DIAGNOSIS OF CARDIOVASCULAR DISEASES

9:00-11:00 SYMPOSIUM 2 HALL 3

DIAGNOSTIC CHALLENGES IN LIVER DISEASE

9:00-11:00 YEAR IN REVIEW 1 HALL

CLINICAL CHEMISTRY 2010 AND BEYOND: OPPORTUNITIES AND CHALLENGES FOR THE NEXT DECADE

9:00-11:00 SYMPOSIUM 3 HALL 14.2

TUMOR MARKERS IN CANCER

9:00-11:00 IFCC 1 HALL 7

e-LEARNING AND DISTANCE EDUCATION IN CLINICAL CHEMISTRY AND LABORATORY MEDICINE

9:00-11:00 SYMPOSIUM 4 HALL 4/5

ACUTE AND CHRONIC KIDNEY DISEASES. AN UPDATE

9:00-11:00 DGKL 1 HALL 9

ROLE OF NON-MEDICAL SCIENTISTS

9:00-10:30 WORKSHOP 1 HALL 10

REPORTING HbA1c FOR MONITORING AND DIAGNOSIS: THE DEVIL'S IN THE DETAIL

11:30-12:45 PLENARY SESSIONS HALL 1

MOLECULAR TUMOR DIAGNOSTICS

13:00 - 14:00 Workshop ORTHO HALL 8

CLINICAL DIAGNOSTICS

TESTING FOR VITAMIN D DEFICIENCY: DEFINING AT-RISK POPULATIONS

13:00 - 14:00 Workshop BECKMAN HALL 14.2

COULTER

CLINICAL AND ECONOMIC ADVANCES IN PROSTATE CANCER DIAGNOSIS

13:00 - 14:00 Workshop ABBOTT HALL 7

IMPORTANCE OF BIOMARKERS IN OPTIMISING THE TREATMENT OF PATIENTS WITH HEART AND KIDNEY DISEASE

13:00 - 14:00 Workshop SYSMEX HALL 4/5

TRUST BY VERIFY: HOW TO EVALUATE HAEMATOLOGY SYSTEMS

13:00 - 14:00 Workshop SIEMENS HALL 9

THE VALUE OF IMPROVED WORKFLOW SOLUTIONS

13:00 - 14:00 Workshop ZMBD HALL 10

IMPACT OF NEW OMICS-PLATFORMS ON BIOMARKERS DISCOVERY AND APPLICATIONS

13:30 - 14:30 POSTER AREA

POSTER WALKS

14:15-15:15 Workshop RANDOX HALL 14.2

THE CLINICAL UTILITY OF MULTIPLEX BIOCHIPS FOR THE DETECTION OF MULTIPLE STI'S AND RESPIRATORY PATHOGENS

14:15-15:15 Workshop A.MENARINI HALL 4/5

SEDIMAX: RECENT AND SIGNIFICANT ADVANCES IN AUTOMATED URINE SEDIMENT EXAMINATION

14:30-16:30 SYMPOSIUM 5 HALL 1

FROM BENCH TO BEDSIDE IN AUTOIMMUNITY

14:30-16:30 SYMPOSIUM 6 HALL 3

DIABETES MELLITUS

14:30-16:00 WORKSHOP 2 HALL 8

EMERGING INFECTIONS AT AFCB COUNTRIES

14:30-16:30 EFCC 1 HALL 7

HOW TO ASSESS THE CLINICAL EFFECTIVENESS OF LABORATORY TESTS?

14:30-16:30 DGKL 2 HALL 9

LABORATORY MEDICINE - QUO VADIS? CONDITIONS, STRUCTURES AND DEVELOPMENTAL TRENDS IN EUROPE

14:30-16:00 INTERACTIVE 2 HALL 10

PITFALLS IN THE HEMOSTASIOLOGIC DIAGNOSTICS: CLINICAL CASES

15:30-16:30 Workshop ORTHO HALL 8

CLINICAL DIAGNOSTIC

ENHANCING PATIENT CARE IN THE CHALLENGING DIAGNOSTIC ARENA IN EUROPE

15:30-16:30 Workshop SARSTEDT HALL 4/5

WORKFLOW OPTIMISATION BY FRONT AND BACK END AUTOMATION IN THE DIAGNOSTIC LABORATORY

16:45-17:45 Workshop CHROMSYSTEMS HALL 8

THERAPEUTIC DRUG MONITORING IN CLINICAL DIAGNOSTICS - FROM RESEARCH TO ROUTINE

16:45-17:45 Workshop ROCHE HALL 14.2

PERSONALISED THERAPIES FOR CHRONIC HEPATITIS B AND C: THE LEADING ROLE OF VIROLOGICAL MARKERS

16:45-17:45 Workshop ABBOTT HALL 7

OVARIAN CANCER BIOMARKERS IN THE CLINICAL CONTEXT - STRATIFICATION AND MONITORING

16:45-17:45 Workshop SEBIA HALL 4/5

HBA1C: EW BREAKTHROUGH TECHNOLOGY FOR LABORATORIES FACING A CHANGE OF PARADIGM

16:45-17:45 Workshop OSM HALL 9

ZENTRALLABOR VS. VERBUNDLABOR

16:45-17:45 Workshop AXIS SHIELD HALL 10

USING ACTIVE B12 TO DIAGNOSE VITAMIN B12 DEFICIENCY

TUESDAY 17 MAY

9:00-11:00 SYMPOSIUM 7 HALL 1

PHARMACOGENETIC AND PHARMACOGENOMIC

9:00-11:00 YEAR IN REVIEW 2 HALL 3

ADVANCES IN CLINICAL CHEMISTRY IN THE FIELD OF NEPHROLOGY AND ENDOCRINOLOGY

9:00-10:30 WORKSHOP 3 HALL 8

OXIDATIVE STRESS IN DIABETES MELLITUS

9:00-11:00 SYMPOSIUM 8 HALL 14.2

INFECTIOUS DISEASES

9:00-11:00 DGKL 3 HALL 7

BIOCHEMICAL ANALYSIS PRIZE - AWARD CEREMONY

9:00-11:00 SYMPOSIUM 9 HALL 4/5

HAEMATOLOGY AND ANEMIA

9:00-11:00 IFCC 2 HALL 9

BIOBANKING AND LABORATORY MEDICINE: TWO RESOURCES FOR MODERN HEALTH CARE

9:00-10:30 WORKSHOP 4 HALL 10

UPDATE ON CARDIAC TROPONIN - CLINICAL AND LABORATORY ISSUES

11:30-12:45 PLENARY SESSIONS HALL 1

ADVANCES IN CLINICAL AND DIAGNOSTIC IMMUNOLOGY

13:00 - 14:00 Workshop RANDOX HALL 8

INCREMENTAL VALUE OF H-FABP IN AN AREA OF HIGHLY SENSITIVE TROPONINS

13:00 - 14:00 Workshop BECKMAN HALL 14.2

COULTER

FROM CLINICAL CHEMISTRY TO MOLECULAR DIAGNOSTICS: INNOVATIVE SOLUTIONS FOR LABORATORY AUTOMATION AND ORGANISATION

13:00 - 14:00 Workshop ABBOTT HALL 7

LABORATORY DIAGNOSIS OF HEPATITIS C - WHAT ARE LOOKING FOR?

13:00 - 14:00 Workshop SYSMEX HALL 4/5

TRUST BY VERIFY: HOW TO EVALUATE HAEMATOLOGY SYSTEMS

13:00 - 14:00 Workshop A.MENARINI HALL 9

FOCUS ON NEW DIAGNOSTIC STRATEGIES IN AUTOIMMUNITY

13:00 - 14:00 Workshop ORTHO HALL 10

CLINICAL DIAGNOSTIC

ENHANCING PATIENT CARE IN THE CHALLENGING DIAGNOSTICS ARENA IN EUROPE

13:30 - 14:30 POSTER AREA

POSTER WALKS

14:15-15:15 Workshop BECKMAN HALL 14.2

COULTER

NEW HORIZONS IN CELLULAR ANALYSIS

14:15-15:15 Workshop SIEMENS HALL 4/5

DIAGNOSTIC AND CLINICAL IMPORTANCE OF MEASURING VITAMIN D TOTAL

14:30-16:30 SYMPOSIUM 10 HALL 1

DIAGNOSTIC USE AND VALUE OF FUCTION TEST IN ENDOCRINOLOGY

14:30-16:30 SYMPOSIUM 11 HALL 3

POINT OF CARE TESTING - PRACTICAL ASPECTS

14:30-16:00 WORKSHOP 5 HALL 8

LESSONS FROM ASIAN-PACIFIC MULTICENTER REFERENCE INTERVAL STUDY

14:30-16:30 DGKL 4 HALL 7

QUALITY MANAGEMENT ACCORDING TO THE GERMAN RILIBAEK: AN INTERNATIONAL PERSPECTIVE

14:30-16:30 EFCC 2 HALL 9

ACCREDITATION SHOULD BE FOCUSSED ON MORE THEN WELL ORGANIZED EXAMINATIONS WITHIN THE LABORATORY

14:30-16:00 WORKSHOP 6 HALL 10

THE 2009 INFLUENZA PANDEMIC - LESSONS LEARNED

15:30-16:30 Workshop ROCHE HALL 14.2

NEXT GENERATION IN CARDIAC BIOMARKERS: LABORATORY MEDICINE'S CONTRIBUTION TO INDIVIDUALIZED TREATMENT IN ACS AND HEART FAILURE

15:30-16:30 Workshop IRIS HALL 4/5

THE CLINICAL UTILITY OF REFLEX URINE CULTURES BASED ON URINALYSIS AND AUTOMATED URINE MICROSCOPY USING THE IQ200 WORKSTATION

16:45-17:45 Workshop HORIBA HALL 8

THE "LEAN" ALTERNATIVE

16:45-17:45 Workshop ROCHE HALL 14.2

EFFICIENT LAB ORGANIZATION FROM PRE-TO POST ANALYTIC

16:45-17:45 Workshop ABBOTT HALL 7

AUTOMATION TO ENSURE YOUR LAB'S EFFICIENCY

16:45-17:45 Workshop BECTON HALL 4/5

DICKINSON

COUNTING THE COST OF THE PREANALYTICAL PHASE

16:45-17:45 Workshop SIEMENS HALL 9

NEW HIGH-PERFORMANCE ASSAYS FOR THE DETERMINATION OF FREE LIGHT CHAIN KAPPA AND LAMBDA - ADDING CONSISTENCY TO MONITORING AND SCREENEING OF MULTIPLE MYELOMA

16:45-17:45 Workshop PERKINELMER HALL 10

CLINICAL MSMS - NEW DEVELOPMENTS IN TODAY'S LABORATORY

WEDNESDAY 18 MAY

9:00-11:00 SYMPOSIUM 12 HALL 1

BIOMARKERS IN ACUTE AND CHRONIC BRAIN DISEASES

9:00-11:00 YEAR IN REVIEW 3 HALL 3

DEVELOPMENTS IN CLINICAL LABORATORY PRACTICE

9:00-10:30 WORKSHOP 7 HALL 8

CLINICAL PHARMACOGENETIC

9:00-11:00 SYMPOSIUM 13 HALL 14.2

PRENATAL AND NEONATAL SCREENING

9:00-11:00 IFCC 3 HALL 7

STANDARDIZATION IN MOLECULAR DIAGNOSTICS

9:00-11:00 SYMPOSIUM 14 HALL 4/5

ALLERGY DIAGNOSTICS

9:00-11:00 DGKL 5 HALL 9

DEVELOPMENT OF A TRANSCRIPTOMIC, PROTEOMIC AND METABOLOMIC DATABASE FOR HUMAN BLOOD CELLS

9:00-10:30 WORKSHOP 8 HALL 10

MOLECULAR DIAGNOSIS OF INFECTION

11:30-12:45 PLENARY SESSIONS HALL 1

THE BRAIN: BIOLOGICAL AND CEREBRAL DISEASES

13:00 - 14:00 Workshop RANDOX HALL 8

THE USE OF MULTIPLEX ASSAYS FOR DETERMINING PREDISPOSITION TO HYPERTENSION

13:00 - 14:00 Workshop BECKMAN HALL 14.2

COULTER

NOVEL MARKERS IN REPRODUCTIVE ENDOCRINOLOGY

13:00 - 14:00 Workshop ABBOTT HALL 7

VITAMIN D AND B12 - IMMUNOASSAYS IN PREVENTIVE MEDICINE

13:00 - 14:00 Workshop SYSMEX HALL 4/5

WORK AREA MANAGEMENT: THE ULTIMATE PRODUCTIVITY TOOL

13:00 - 14:00 Workshop THE HALL 9

BINDING SITE

Freelite™ AND Hevylite™ IN MONOCLONAL GAMMAPATHIES: IMPROVING DIAGNOSIS, MONITORING AND PROGNOSIS ASSESSMENT

13:00 - 14:00 Workshop DIASORIN HALL 10

VITAMIN D DIETARY REFERENCE INTAKES: IMPLICATIONS AND SIGNIFICANCE IN CLINICAL PRACTICE

13:30 - 14:30 POSTER AREA

POSTER WALKS

14:15-15:15 Workshop ROCHE HALL 14.2

PERSONALISED HEALTHCARE AS A KEY DRIVER FOR PRESENT AND FUTURE DIAGNOSTIC/THERAPEUTIC STRATEGIES

14:15-15:15 Workshop DIASYS HALL 4/5

A NEW PROSPECTIVE FOR THE AUTOMATION OF CLINICAL CHEMISTRY TESTING

14:30-16:30 SYMPOSIUM 15 HALL 1

NEW DEVELOPMENTS IN HAEMOSTASEOLOGY

14:30-16:30 SYMPOSIUM 16 HALL 3

CONTRIBUTION OF LABORATORY MEDICINE IN LEUKEMIA

14:30-16:00 WORKSHOP 9 HALL 8

WHAT PAPERS WILL BE PREFERRED IN THE FUTURE RELATED TO LABORATORY MEDICINE?

14:30-16:30 EFCC 3 HALL 7

A SCIENTIFIC APPROACH TO THE POST-ANALYTICAL PHASE

14:30-16:30 DGKL 6 HALL 9

RESEARCH FUNDING BY THE FOUNDATION OF PATHOBIOCHEMISTRY AND MOLECULAR DIAGNOSTICS OF THE DGKL

14:30-16:00 INTERACTIVE 1 HALL 10

CHALLENGES AT THE CLINICAL INTERFACE

15:30-16:30 Workshop RANDOX HALL 14.2

CURRENT AND FUTURE PERSPECTIVES IN DRUGS OF ABUSE SCREENING; THE MULTIPLEX APPROACH

15:30-16:30 Workshop BIOSYSTEMS HALL 4/5

TRACEABILITY AND UNCERTAINTY OF CATALYTIC ACTIVITY MEASUREMENTS

THURSDAY 19 MAY

9:00-11:00 SYMPOSIUM 17 HALL 1

NEW STRATEGIES IN MOLECULAR DIAGNOSTIC

9:00-11:00 SYMPOSIUM 18 HALL 3

STANDARDIZATION AND QUALITY CONTROL ISSUES IN EMERGING AND DEVELOPING COUNTRIES

9:00-10:30 WORKSHOP 10 HALL 8

STANDARDIZATION OF COMPLEX ANALYTE MEASUREMENT: THE CLINBIOTRACE PROJECT

9:00-11:00 SYMPOSIUM 19 HALL 14.2

CURRENT CHALLENGES IN THE PEDIATRIC LABORATORY

9:00-11:00 EFCC 4 HALL 7

STANDARDIZATION OF THE PRE-ANALYTICAL PHASE FOR BIOMARKERS

9:00-11:00 SYMPOSIUM 20 HALL 4/5

VITAMIN D: MYTH OR MAGIC

9:00-10:30 WASPaLM WS HALL 9

CHRONIC KIDNEY DISEASE - DEVELOPING A NATIONAL TESTING PROGRAM

9:00-10:30 WORKSHOP 11 HALL 10

BIOMARKERS OF ACUTE AND NEURODEGENERATIVE BRAIN DAMAGES

11:30-12:45 PLENARY SESSIONS HALL 1

NEW AVENUES IN LABORATORY DIAGNOSTICS

13:00 - 14:00 Workshop LABS ARE HALL 8

VITAL

ADDING VALUE TO LABORATORY MEDICINE

13:00 - 14:00 Workshop WATERS HALL 9

LC/MS IN THE CLINICAL LABORATORY - TRANSITION FROM A RESEARCH TOOL TO ROUTINE CLINICAL LABORATORY USE

14:30-16:30 SYMPOSIUM 21 HALL 1

NEW TECHNOLOGIES IN CLINICAL APPLICATION

14:30-16:30 SYMPOSIUM 22 HALL 3

INTERWINING EMERGENCY MEDICINE AND LABORATORY MEDICINE

14:30-16:00 WORKSHOP 12 HALL 8

TRENDS IN THERAPEUTIC DRUG MONITORING: PERSONALIZED IMMUNOSUPPRESSION

14:30-16:30 IFCC 4 HALL 7

TRACEABILITY, STANDARDIZATION, HARMONISATION: CONCEPTS AND IMPLEMENTATION

14:30-16:00 WORKSHOP 13 HALL 9

VITAMIN DEFICIENCY IN ELDERLY PEOPLE: DIAGNOSIS, PREVENTION AND EFFECT ON AGE-RELATED DISEASES

14:30-16:00 WORKSHOP 14 HALL 10

NOVEL INSIGHTS IN IRON METABOLISM: IMPLICATIONS FOR DIAGNOSTIC MEDICINE

16:30-17:30 HALL 1

CLOSING CEREMONY

SOCIAL EVENTS

Sunday 15 May

19:30 Welcome Party

Monday 16 May

20:00 Presidents' Dinner at Adlon Hotel
By invitation only

Wednesday 18 May

19:30 Congress Party at Museum Island

- **A t a g l a n c e** -

Printed as of April 2011

WELCOME ADDRESSES and COMMITTEES

pages 2 - 10

Welcome to the IFCC-WorldLab-EuroMedLab Berlin 2011	2
IFCC - <i>International Federation of Clinical Chemistry and Laboratory Medicine</i>	3
EFCC - <i>European Federation of Clinical Chemistry and Laboratory Medicine</i>	4
DGKL - <i>German Society of Clinical Chemistry and Laboratory Medicine</i>	5
Welcome from Local Authorities	6
Committees	8
Executive Boards	9
Travel Grants	10

SCIENTIFIC PROGRAM

pages 11 - 90

Sunday 15 May	12
Monday 16 May	15
Tuesday 17 May	34
Wednesday 18 May	53
Thursday 19 May	68
Speakers and Chairs	80

POSTERS

pages 93 - 172

Information and Map	94
Poster List	97

GENERAL INFORMATION

pages 175 - 188

Information	176
Social Events	185
Tourist Information	187

SPONSORS & EXHIBITORS

pages 190 - 257

Platinum Sponsors	191
Gold Sponsors	194
Bronze Sponsors	195
Exhibitors	201
Sponsors	249
Exhibition Area Maps	250

Program at a glance

Front fold out

Dear Participants of IFCC-WorldLab-EuroMedLab Berlin 2011,
Dear Colleagues and Friends,

It is with great pleasure to welcoming you here in Berlin, the capital of reunited Germany!

It is a great privilege and honour for us to host this major joint event of Laboratory Medicine and Clinical Chemistry here in our country. The 21st International Congress of Clinical Chemistry and Laboratory Medicine will take place together with the 19th European Congress of Clinical Chemistry and Laboratory Medicine as well as with the 8th Annual Meeting of the German Society of Clinical Chemistry and Laboratory Medicine.

We would like to thank the International Scientific Committee (ISC) in bringing together a highly attractive and up-to-date scientific program, consisting of 12 plenary lectures in four sessions, 22 symposia, interactive sessions, 14 workshops and more than 40 industry-sponsored workshops.

Altogether we have invited more than one hundred speakers from around the world to deliver to you all facets of our discipline ranging from basic science and translational research to clinical practice.

In addition to these classical types of scientific sessions, we will also offer new types of formats such as "The Year in Review", "Clinical Case Conferences" and other highly interactive formats to discuss cutting-edge science in our field.

In addition to science, Berlin is one of the most vibrant cities in Germany and Europe and represents, therefore, an ideal platform to provide not only an international exchange of knowledge and ideas, but also to foster friendship and collegiality among the participants from around the world. In addition to the scientific program, a rich social program providing the frame for relaxation and cultural stimulation has been developed for attendees, families and friends. Particularly, we would like to draw your attention to the Congress Evening on Wednesday with an exclusive visit to the Museum Island, a World Heritage.


The motto of our conference, **Fit for future - Help healing the World**, emphasizes and underscores the importance of laboratory medicine in patient care. However, we all know that this goal is very ambitious and many research efforts are necessary to eventually reach this equation.

The realization of this Congress is only possible with the generous support of the Diagnostic Industry. We would like to thank all sponsoring companies for their help and willingness to actively participate in this event. Please use the time slots for visiting the large exhibition area which offers a view on the most recent technological and diagnostic advancement in laboratory medicine!

Therefore, a warm welcome to Berlin!

Harald Renz
President

Rudolf Tauber
President





International Federation of Clinical Chemistry and Laboratory Medicine



The International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) is proud to host IFCC WorldLab Berlin 2011.

IFCC is a global professional organization serving a worldwide partnership of clinical laboratory scientists, laboratory physicians and specialists within the in-vitro diagnostics industry. Founded in 1952 the IFCC membership currently comprises 85 national societies and 42 companies who together represent more than 30,000 laboratory medicine specialists.

The IFCC mission statement is: "Through leadership and innovation in science and education:

- We strive to enhance the scientific level and the quality of diagnosis and therapy for patients throughout the world
- We build on the professionalism of our members to provide quality services to patients
- We communicate effectively with our members, other healthcare providers and the public to ensure knowledge of our excellent scientific and educational achievements
- We focus on scientific standards, publications, education and communications
- We hold outstanding congresses and conferences throughout the world to bring the efforts of IFCC to the global community.

The current priorities for IFCC are:

- To complement and enhance the activities of its members
- To share examples of good practice and to promote the contribution and added value of clinical chemistry and laboratory medicine
- To transcend geographical and corporate boundaries by developing global programmes for clinical chemistry and laboratory medicine
- Through the Scientific Division (SD) to provide a forum for standardization and traceability, with the establishment of reference systems to improve the quality of health care for individuals and communities
- Through the Education and Management Division (EMD) to provide IFCC members and the healthcare community with relevant education directed at clinical, scientific, and management issues, especially in developing countries
- Through the Communication and Publications Division (CPD) to communicate and promote the work and image of IFCC to clinical laboratory scientists, physicians and health care policy makers worldwide.

The IFCC has extensive co-operation and direct collaboration with a large number of international organizations which are active in clinical, scientific and educational areas of common interest.

The Officers of IFCC are always keen to communicate with members, other organizations and with individuals on matters relating to clinical chemistry and laboratory medicine. Please visit the IFCC website (www.ifcc.org) and/or contact the President, Graham Beastall (president@ifcc.org) or the Secretary, Paivi Laitinen (secretary@ifcc.org).

Graham Beastall
IFCC President



European Federation of Clinical Chemistry and Laboratory Medicine

Dear Colleagues,

It is a pleasure to welcome you at the joint IFCC WorldLab and EuroMedLab Congress 2011 in Berlin, the second most populous and one of the most vibrant cities of Europe. Berlin is among the top three convention cities in the world, where research and development have established economic significance, and the Berlin Brandenburg region ranks among the top three innovative regions in the European Union.



Thus there is no doubt that Berlin, with its history and resources, provides an infrastructure which enables all attendees to meet their needs and to enjoy the scientific, cultural and social opportunities that this Congress offers. As one would expect there is a wide-ranging high quality scientific program covering the cutting-edge developments in laboratory medicine. The scientific program of the Congress demonstrates the invaluable role that Laboratory Medicine plays in health care. Main conference topics include the role of prevention, theragnostics, new technologies and biomarkers in the era of "omics", the relevance of automation and IT, and the education and training of our future professionals to cope with these challenges, particularly in a demanding and difficult economic environment.

This conference will be an opportunity to meet old friends and make new ones to interact with like-minded colleagues in the pursuit of common goals and interests in the ongoing development of clinical chemistry and laboratory medicine.

After the fall of the Berlin Wall in November 1989 the Brandenburg Gate, enhancing the approach into the Boulevard Unter den Linden, became not only a historical landmark but also the symbol of unity. So, let us unite the profession in Europe and all over the world in the exciting city of Berlin!

Whether on the congress floor or sampling the attractions of Berlin, I am sure you will enjoy your attendance at a memorable meeting. EFCC welcomes you for an enriching professional conference and friendly exchanges Unter den Linden!

Andrea Rita Horvath
EFCC President



German Society of Clinical Chemistry and Laboratory Medicine



Dear Delegates,
dear Colleagues,

It is my pleasure to welcome you to the 21st International Congress of Clinical Chemistry and Laboratory Medicine in Berlin organized by IFCC, EFCC, and DGKL. As one of the oldest scientific societies devoted primarily to this field of medicine we are proud to host scientists from all over the world on this occasion. The congress presidents Harald Renz and Rudolf Tauber supported by an international congress organizing committee and a scientific advisory board have assembled a program delineating the state of the art of our profession. Looking at the final program it is clear that the hard work of the last three years has led to what can be expected from an outstanding congress. It will underscore the immense impact of laboratory diagnostics on all areas of modern medicine. During the congress there will be ample opportunity for scientific exchange among the delegates and with the invited speakers. Plenary sessions, parallel symposia, industry sponsored workshops, and poster sessions provide the stage for in depth discussions, and I encourage you to take this opportunity. During the meeting the IFCC, EFCC, and DGKL will also award their renowned prizes for scientific and professional achievements among them the Biochemical Analysis Prize of the DGKL with a tradition of more than 40 years. Among the list of prize winners are 5 scientists who were later awarded the Nobel Prize.

All this is embedded in the vibrant city of Berlin which offers a wealth of cultural experiences. One of them – the world famous Museum Island – will open its doors exclusively for congress delegates and their company on Wednesday evening. You will have time to visit the unique treasures among them the Pergamon Altar and Nefertiti. I expect this to become an unforgettable congress highlight.

I wish that all of you enjoy your stay in Berlin and remember the congress as an exciting and stimulating scientific event that was well worth the travel.

Karl J. Lackner
President DGKL

W
e
l
c
o
m
e



**Bundesministerium
 für Bildung
 und Forschung**

Message from the Federal Minister of Education and Research, Annette Schavan

Increasingly detailed knowledge about the causes of diseases and new diagnostic technologies are vital prerequisites for medical innovations. Modern laboratory equipment contributes to diagnosing diseases more quickly, more reliably and at an earlier stage. As a result, treatment can be initiated more promptly and in a more targeted way. The aim of individualized medicine is to choose the therapy that is best suited to the patient, avoiding side effects wherever possible. More precise diagnostic tools do not just enable individually tailored treatments - innovative laboratory diagnostics and bioinformatics also change the way in which new drugs are developed.



Health research plays an important role in the Federal Government's High-Tech Strategy: since 2007, approximately 800 million euros have been provided for efforts to strengthen basic research and accelerate the transfer of research results to the treatment of patients. During this period, the Federal Ministry of Education and Research has invested 30 million euros in molecular diagnostics alone to ensure that Germany remains a competitive, forward-looking research location in the field of laboratory medicine. After all, the molecular diagnostics market is also important from an economic point of view. It is currently worth 12 billion euros, and experts predict that it will grow to approximately 22.5 billion euros over the next five years.

We are facing great challenges in the 21st century - particularly in the field of health research. Demographic change and the rapidly increasing prevalence of certain diseases pose great challenges in the area of health research. To meet them, we need modern health research in all fields of science, and we expect a great deal from the area of laboratory medicine. I would like to thank the organizers of this year's International Congress of Clinical Chemistry and Laboratory Medicine in Berlin for their great commitment. I hope that the event will provide a forum for interesting conversations and discussions, stimulate new ideas for future research activities, and present important information for medical practitioners.

Prof. Dr. Annette Schavan
 Federal Minister of Education and Research

Message from the Governing Mayor of Berlin, Klaus Wowereit, for the IFCC WorldLab 2011 in Berlin



IFCC WorldLab EuroMedLab is one of the world's largest and most important scientific congresses, and Berlin is greatly honored to be hosting the national and international experts working in this field. You will feel at home in Berlin, which is a city of great scientific capability.

Medicine, research, and academics occupy a special position in Berlin. Universities and many non-university research institutes of international renown work together closely here. Networks within disciplines promote cooperation between science and business, and many of our medical products and services are unique in their fields.

Berlin is very well prepared to host large national and international congresses and trade fairs. The International Congress Center (ICC); Messe Berlin, our trade fair company; and many other conference facilities offer excellently equipped premises for concentrated professional interaction, and Berlin's hotels and atmospheric restaurants offer inviting opportunities for culinary exploration.

Those attending a conference on the banks of the Spree should not forget to take a look at the city's cultural calendar. Whether theater or opera, classical music or jazz, ancient sculpture or contemporary art – Berlin has something for everyone.

Berlin is welcoming the IFCC WorldLab-EuroMedLab participants.

Klaus Wowereit
Governing Mayor of Berlin

CONGRESS ORGANIZING COMMITTEE

T. Brinkmann (Switzerland)
 J. Klabunde (Germany)
 K.J. Lackner (Germany)
 T. Ozben (Turkey)
 H. Renz (Germany)
 R. Tauber (Germany)

INTERNATIONAL SCIENTIFIC COMMITTEE

H. Renz (Germany) - Chairman	H. Morris (Australia)
R. Tauber (Germany) - Vice Chairman	M. Neumaier (Germany)
V. Blaton (Belgium)	T. Nobori (Japan)
K. Brand (Germany)	T. Ozben (Turkey)
T. Brinkmann (Switzerland)	M. Panteghini (Italy)
B. Croal (United Kingdom)	M. Pilonetto (Brazil)
A. Hedili (Tunisia)	K. Pulkki (Finland)
J. Hicks (USA)	R. Sierra Amor (Mexico)
A.R. Horvath (Hungary)	C. Wagener (Germany)
K.J. Lackner (Germany)	U. Walter (Germany)
C. Lam (Hong Kong)	J. Wesenberg (Canada)
D. Mazziotta (Argentina)	M.A. Zablitt (Lebanon)

INTERNATIONAL SCIENTIFIC ADVISORY BOARD

H. Renz (Germany) - Chairman	D. Popovic (Montenegro)
A.A. Buló (Albania)	D.W. Swinkels (The Netherlands)
A. Hooper (Australasia)	M.A. Charles-Davies (Nigeria)
A. Griesmacher (Austria)	A.L. Biorke Monsen (Norway)
J.P. Chapelle (Belgium)	M.M. Blanes Gonzalez (Paraguay)
K. Tzatchev (Bulgaria)	J. Ortellado de Canese (Paraguay)
P. St. Louis (Canada)	G. Sypniewska (Poland)
E. Aranda (Chile)	G. de Sousa (Portugal)
A. Simundic (Croatia)	G. Benga (Romania)
T. Zima (Czech Republic)	M. Cojocarú (Romania)
K. Tomberg (Estonia)	V.V. Menshikov (Russia)
K. Pulkki (Finland)	N. Majkic-Singh (Serbia)
P. Gillery (France)	K. Danova (Slovakia)
A. Chaliassos (Greece)	V. Steenkamp (South Africa)
H.M. Chan (Hong Kong)	J.M. Queralto (Spain)
A.R. Horvath (Hungary)	E. Theodorsson (Sweden)
J.J. Jonsson (Iceland)	A. von Eckardstein (Switzerland)
P. Mocarelli (Italy)	L. Risch (Switzerland)
M. Plebani (Italy)	F. Harb (Syrian Arab Republic)
T. Nobori (Japan)	A. Hedili (Tunisia)
Y.Y. Bilto (Jordan)	N. Ozer (Turkey)
J.Q. Kim (Korea)	M. Hallworth (United Kingdom)
O.H. Kwon (Korea)	
G. Gilson (Luxemburg)	
J.F. Muñoz Valle (Mexico)	

IFCC - International Federation of Clinical Chemistry and Laboratory Medicine

G. Beastall (United Kingdom) - President
 C. Lam (Hong Kong) - Vice-President
 J. M. B. Hicks (USA) - Past President
 P. Laitinen (Finland) - Secretary
 G. Shannan (Syria) - Treasurer
 T. Brinkmann (Switzerland) - Corporate Representative
 B. Gouget (France) - Member
 J. B. Lopez (Malaysia) - Member
 U. Tuma (Brazil) - Member

EFCC - European Federation of Clinical Chemistry and Laboratory Medicine

A. R. Horváth (Australia) - President
 I. D. Watson (United Kingdom) - President-Elect
 V. Blaton (Belgium) - Past President
 H. J. van Pelt (The Netherlands) - Secretary
 P. Schuff-Werner (Germany) - Treasurer
 M. Pazzagli (Italy) - Member-at-large
 K. Pulkki (Finland) - Member-at-large

DGKL - German Society for Clinical Chemistry and Laboratory Medicine

K. Lackner (Germany) - President
 J. Thiery (Germany) - Vice-President
 K. Kohse (Germany) Secretary
 H. Patscheke (Germany) - Treasurer
 R. Lichtinghagen (Germany) - Additional Member
 J. Aufenanger (Germany) - Additional Member

ORGANIZING SECRETARIAT



MZ Congressi s.r.l.

Member of the MZ International Group (Milano, Torino, Barcelona, London)

Individual Company subject to management and coordination by MZ International Group srl

Sistema di Gestione certificato secondo la Norma ISO 9001:2008

Via Carlo Farini 81 - 20159 Milano, Italy

Phone +39 02 66802323 - Fax +39 02 6686699

e-mail: info@berlin2011.org



Travel Grants

WINNERS

ESSIARAB FADWA
 GUPTA MONIKA
 NEPAL ASHWINI
 REVERENDO MARIA AMELIA
 SHRESTHA ROJEET
 AJILI FAOUZIA
 CORT AYSEGUL
 DUJIC TANJA
 EL BAZ HATIM
 JACOBS LEO
 WAFULA BRAMWEL BARAZA
 ISFER OLIVEIRA MAUREN
 SZOKE DOMINIKA
 BRAGA FEDERICA
 ARPPE RIIKKA
 DMYTRUK IRINA
 OOSTENDORP MARLIES
 FOROUGH FOROUGH
 CULEJ JELENA
 DZIEGIELEWSKA SYLVIA
 MOHAN TEENA

MOROCCO
 INDIA
 NEPAL
 ARGENTINA
 NEPAL
 TUNISIA
 TURKEY
 BOSNIA
 EGYPT
 THE NETHERLANDS
 KENYA
 BRAZIL
 ITALY
 ITALY
 FINLAND
 UCRAINA
 THE NETHERLANDS
 IRAN
 CROATIA
 POLAND
 INDIA

KINDLY SUPPORTED BY:



➤ **Scientific Program**

17:30 - 19:30

HALL 1

OPENING CEREMONY

Musical Introduction

*A Time to Make Good Friends.
Welcome to Germany! Welcome to Berlin!*

Berlin Symphony

Welcome Addresses

Congress Presidents, *Rudolf Tauber, Harald Renz*
IFCC President, *Graham Beastall*
EFCC President, *Andrea Rita Horvath*
DGKL President, *Karl Lackner*

*Fit For Future
Help healing the World*

"Heal the world"

Berliner Rundfunk Kinderchor & Jugendorchester

Awards Presentation

IFCC Distinguished Clinical Chemist Award - *Sponsored by Beckman Coulter*
IFCC Henry Wishinsky Award for Distinguished International Services -
Sponsored by Siemens
IFCC Award for Distinguished Contributions in Education - *Sponsored by Abbott Diagnostics*
IFCC Award for Significant Contributions in Molecular Diagnostics -
Sponsored by Abbott Molecular
IFCC Distinguished Award for Laboratory Medicine and Patient Care - *Sponsored by IFCC*
IFCC Robert Schaffer Award for Outstanding Achievements in the Development of
Standards for Use in Laboratory Medicine - *Sponsored by NIST - CLSI*
IFCC Young Investigator Award - *Sponsored by Roche*
EFCC Scientific Award for Laboratory Medicine - *Sponsored by Roche*
EFCC Labs Are Vital Award for Excellence in Outcomes Research in Laboratory Medicine -
Sponsored by Abbott
DGKL Prize "Biochemical Analysis" - *Sponsored by Sarstedt*

"We are the world"

Berliner Rundfunk Kinderchor & Jugendorchester

Opening Lecture

The Evolution of Medicine to Evolutionary Medicine

Detlev Ganten

Drumshow
Berlin Drum Company

After the opening ceremony, you are kindly invited to take part in the Welcome Party.

Follow the Presidents of the Congress and the Berlin Drum Company !!

OPENING LECTURE

The Evolution of Medicine to Evolutionary Medicine

Detlev Ganten (Germany)

President World Health Summit - Charité - Universitätsmedizin Berlin



Professor Ganten was born in Lüneburg in 1941. He studied medicine at the universities of Würzburg, Montpellier (France) and Tübingen. After taking his degree, he spent several years as a research scientist at the Clinical Research Institute in Montreal (Canada), and earned his Ph.D. at McGill University. In 1975 Detlev Ganten was appointed Professor at the Department of Pharmacology at the University of Heidelberg. From 1991 to 2004 Professor Ganten was the Founding Director and President of the Max Delbrück Center for Molecular Medicine (MDC) Berlin-Buch. He also was Director of the Department of Pharmacology at the Benjamin Franklin Medical Center of the Free University of Berlin. From 2004 to 2008

Professor Ganten was Chief Executive Officer at the “Charité –Universitätsmedizin Berlin”, the joint medical faculty of the Free University and Humboldt University of Berlin. Since 2005 Professor Ganten is the Chairman of the Foundation Board of the Charité Foundation. Since 2009 he is also Chairman of the joint Board of Trustees of the Max Planck Institute of Colloids and Interfaces and of the Max Planck Institute of Molecular Plant Physiology (Berlin-Potsdam), and he is President of the World Health Summit. As a research scientist in the field of hypertension, Professor Ganten elucidated fundamental mechanisms of the pathophysiology and molecular biology of high blood pressure. His area of research includes the hormonal regulation of blood pressure, especially the renin-angiotensin system, and the molecular genetics of cardiovascular diseases and evolutionary medicine.

ABSTRACT

The human body, its organs, cell function, biochemistry and our genes are the result and a living archive of evolution. Many evolutionary mechanisms are now understood in detail on a molecular and genomic basis. This opens up new vistas to a better understanding of the basis of health and disease. In addition to asking proximate questions how a disease mechanism is best understood, we can start investigating ultimate questions why we get sick. The gap between evolutionary old body functions on the one hand and modern lifestyles in new urban societies on the other hand results in diseases of civilization. Evolutionary Darwinian Medicine makes use of these new insights for research, diagnosis, treatment and prevention of disease.

Sunday 15 May

CLOSED MEETINGS

9:00-13:00 Hall 8

IFCC Council

8:30-17:00 Room 47

IFCC C-AQ

Co-Chairs: E. Amann, J. Gill

8:30-18:00 Room 50

IFCC SD-EC

Chair: I. Young

9:00-13:00 Room 46

IFCC C-CC

Chair: T. Ozben

9:00-17:00 Salon 19

IFCC C-RIDL

Chair: K. Ichihara

13:30-17:00 Hall 8

EFCC General Assembly

13:30-14:30 Salon 20

IFCC TF-HbA1c

Chair: G. John

14:30-17:00 Salon 20

HbA1c Network Laboratories

Open Meeting

Chair: C. Weykamp

15:00-17:00 Room 48

IFCC e-News

Chair: E. Delvin

9:00 - 11:00

PARALLEL SESSIONS

Symposium 1**HALL 1****BIOMARKERS FOR THE DIAGNOSIS OF CARDIOVASCULAR DISEASES**

Chairs: I. Young (United Kingdom), A. von Eckardstein (Switzerland)

- 9:00** Clinical implication of high sensitive troponin testing
S. Blankenberg (Germany)
- 9:25** Quality specifications for troponin assays
R. Christenson (USA)
- 9:50** Cellular and molecular imaging
R. Choudhury (United Kingdom)
- 10:15** BNP and heart failure
C. Müller (Switzerland)
- 10:40** High sensitive cardiac troponin T in the clinical work-up of patients with stable chest pain
A.M.A. Mingels (The Netherlands)
- 10:50** I-PRESERVE sub-study: Plasma collagen markers in the prediction of death and hospitalisation in patients with heart failure and preserved ejection fraction
H.G Schneider (USA)

Symposium 2**HALL 3****DIAGNOSTIC CHALLENGES IN LIVER DISEASE**

Chairs: F. Ceriotti (Italy), B. Gouget (France)

- 9:00** Non-alcoholic fatty liver disease (NAFLD)
V. Ratzu (France)
- 9:25** Biomarkers of fibrogenesis for the diagnosis and the activity of the fibrosis process in liver diseases
M. Vaubourdolle (France)
- 9:50** Hepatocellular carcinoma: Molecular pathogenesis and clinical aspects
H. Blum (Germany)
- 10:15** Occult hepatitis B infection: Diagnosis and significance
W. Gerlich (Germany)
- 10:40** Plasma levels of soluble CD30 and CD40L in pediatric patients after liver transplantation
O. Shevchenko (Russia)
- 10:50** Serological markers of gastric pathology
A. Caleffi (Italy)

9:00 - 11:00

PARALLEL SESSIONS

Year in Review 1

HALL 8

CLINICAL CHEMISTRY 2010 AND BEYOND: OPPORTUNITIES AND CHALLENGES FOR THE NEXT DECADE

Chairs: V. Blaton (Belgium), N. Rifai (USA)

- 9:00** Next-generation sequencing of plasma DNA for molecular diagnosis
D. Lo (Hong Kong)
- 9:30** Drugs of abuse testing, from urine to oral fluid: Scientific and legal ramifications
M. Huestis (USA)
- 10:00** Laboratory and clinical implications of high-sensitivity troponin assays
F. Apple (USA)
- 10:30** The diagnostic proteome: Prospects for biomarker discovery and validation in plasma
L. Anderson (USA)

Symposium 3

HALL 14/2

TUMOR MARKERS IN CANCER

Chairs: M. Neumaier (Germany), T. Zima (Czech Republic)

- 9:00** Circulating tumor cells and bone marrow micrometastases
K. Pantel (Germany)
- 9:25** Measurement and diagnostic use of Prostate-Specific Antigen (PSA)
U.H. Stenman (Finland)
- 9:50** Biomarkers and personalized models in oncology drug development
D. Sidransky (USA)
- 10:15** Proteomic approaches for novel biomarker discovery
V. Kulasingam (Canada)
- 10:40** KLK3 and steroid 5-alpha reductase type II (SRD5A2) gene polymorphisms might affect clinical reliability of serum PSA measurement
C.-F. Zambon (Italy)
- 10:50** DNA methylation of tumor suppressor and metastasis suppressor genes in circulating tumor cells
S. Lianidou (Greece)

9:00 - 11:00

PARALLEL SESSIONS

Symposium**HALL 7****eLEARNING AND DISTANCE EDUCATION IN CLINICAL CHEMISTRY AND LABORATORY MEDICINE**

Chair: E. Jacobs (USA)



- 9:00** Webinars, steaming media, blogs and other e-communications
A. Lyon (Canada)
- 9:30** Labtestsonline: Transmitting laboratory medicine in the context of national and international guidelines
M. Klouche (Germany)
- 10:00** IFCC experiences with distance learning
E. Jacobs (USA)
- 10:30** e-Learning experiences of National Societies of Clinical Chemistry and Laboratory Medicine
P. Kocna (Czech Republic)

Symposium 4**HALL 4/5****ACUTE AND CHRONIC KIDNEY DISEASES. AN UPDATE**

Chairs: N. Greenberg (USA), N. Ozer (Turkey)

- 9:00** Unmet clinical needs in assessing CKD
G. Jones (Australia)
- 9:25** Cystatin C for estimation of renal function in CKD
A. Grubb (Sweden)
- 9:50** Biomarkers of acute kidney injury
C. Ronco (Italy)
- 10:15** Dyslipidemia of chronic renal disease
O. Samuelsson (Sweden)
- 10:40** Pregnancy associated plasma protein-A (PAPP-A) as a mortality predictor of long-term hemodialysis patients
M. Kalousová (Czech Republic)
- 10:50** An error propagation formula must be used to correctly calculate uncertainty in EGFR
D.M. Parry (Canada)

9:00 - 11:00

PARALLEL SESSIONS

Symposium **HALL 9**
ROLE OF NON-MEDICAL SCIENTISTS

Chair: W. Dick (Germany)



- 9:00** Scientific methods in medicine
W. Bauersfeld (Germany)
- 9:30** The advance of the science in medicine
G. Raabe-Meyer (Germany)
- 10:00** Medical laboratory manager – Non-analytical work
R. Lichtinghagen (Germany)
- 10:30** Requirements for excellence in laboratory medicine –
A melting pot of biosciences and medicine
N. Gässler (Germany)

Simultaneous translation from German to English will be provided



Workshop 1 **HALL 10** **9:00-10:30**
REPORTING HbA1c FOR MONITORING AND DIAGNOSIS:
THE DEVIL'S IN THE DETAIL

Chair: B. Croal (United Kingdom)

- 9:00** Estimated average glucose 2 years on
E.S. Kilpatrick (United Kingdom)
- 9:30** Status of HbA1c measurement and goals for improvement
R. Little (USA)
- 10:00** EQA: HbA1c fit for the diagnosis of diabetes?
C.W. Weykamp (The Netherlands)

11:30-12:45

PLENARY SESSION

MOLECULAR TUMOR DIAGNOSTICS

HALL 1

Chairs: G. Beastall (United Kingdom), K. Lackner (Germany)

11:30

The potential impact of individualized therapy approaches on pediatric cancer clinical research: Technology validation and global access

G. H. Reaman (USA)



Gregory H. Reaman, M.D., is Chair of the Children's Oncology Group (COG) since its inception in 2000. The COG is comprised of over 200 member institutions, dedicated to clinical, translational, and epidemiology research in childhood cancer throughout North America, Australia, and New Zealand.

Dr. Reaman is a Professor of Pediatrics at The George Washington University School of Medicine and Health Sciences and a member of the Division of Hematology-Oncology at the Children's National Medical Center in Washington, D.C., which he directed for nearly 18 years.

Dr. Reaman serves or has served on the Editorial Boards of *Leukemia*, *Journal of Clinical Oncology*, *Journal of Pediatric Hematology/Oncology*, *Pediatric Blood and Cancer*, *The Oncologist*, *Cancer*, and *Physicians Data Query (PDQ)*, National Cancer Institute as well as the ASCO Cancer Foundation's (www.cancer.net). He has served as an Associate Editor of *Cancer and Leukemia and Lymphoma*.

11:55

Cancer gene expression: A systems biology approach to biomarker and drug development

W. N. Keith (United Kingdom)



Nicol Keith obtained his undergraduate training in genetics at Edinburgh University before undertaking his PhD studies at the CRUK Beatson Institute for Cancer Research in Glasgow. After post-doctoral research in areas related to cancer drug resistance, he established his research program in the Department of Medical Oncology at Glasgow University. In 2004 he became Professor of Molecular Oncology at the Centre for Oncology & Applied Pharmacology of Glasgow University. Nicol's research is focused on the development of

novel therapeutics that target cellular senescence and telomerase. The approach is based on integrating within a bioinformatic framework a wide variety of external and in-house data sources with high content screening. Nicol is a founder and Director of Senectus Therapeutics Ltd. a drug discovery company focused on the development of novel therapeutics that target cellular senescence. Nicol is a member of several national and international scientific committees and is particularly active within the International Union Against Cancer (UICC) including chairing the UICC International Cancer Technology Transfer Fellowships (ICRETT) & YY grants committee's which facilitate rapid international transfer of cancer research techniques and technology and clinical management skills across the globe.

12:20

Posttranslational modifications in tumor diagnosis

C. Wagener (Germany)



Professor Christoph Wagener is director of the Department of Clinical Chemistry in the Center for Diagnostic of the University Medical Center Hamburg-Eppendorf, Germany. The central laboratories of the clinic are part of the institute. C. Wagener was Dean of the Medical Faculty and President of the German Society of Clinical Chemistry and Laboratory Medicine. Molecular tumor diagnostics is the main research focus of his institute. Specifically, posttranslational modifications such as phosphorylation and glycosylation are characterized by the use of human protein domains involved in molecular recognition.

13:30-14:30

POSTER WALKS

Poster Area

In order to encourage discussions, poster walks will be held on Monday, Tuesday, and Wednesday from 13:30 to 14:30. The author of the selected posters is asked to be by his/her poster panel from 13:30 to 14:30. Each author will have up to three minutes to present the poster.

The chairman selected for each poster walk will guide the walk and chair the discussion.

All delegates wishing to attend poster walks must be at the first poster panel (see poster-panel code) at 13:30.

Autoimmune disease

Chair: U. Sack (Germany)

Posters

0024	0037	0044	0051
0028	0039	0046	0052
0032	0043	0050	0055

Cancer/tumor markers

Chair: C. Wagener (Germany)

Posters

0069	0085	0096	0143
0083	0088	0098	0160
0084	0092	0105	0162

Cancer/tumor markers

Chair: M. Kiehntopf (Germany)

Posters

0103	0125	0144	0152
0116	0128	0146	0157
0118	0142	0149	0159

Cardiovascular disease

Chair: A. von Eckardstein (Switzerland)

Posters

0176	0196	0214	0222
0180	0197	0219	0223
0194	0210	0218	0238

Critical care/emergency medicine

Chair: H. van Pelt (The Netherlands)

Posters

0309	0313	0317	0323
0310	0314	0318	0326
0311	0315	0319	0335

Diabetes mellitus and metabolic syndrome

Chair: T. Zima (Czech Republic)

Posters

0349	0355	0375	0380
0352	0358	0376	0386
0353	0361	0377	0398

Endocrinology

Chair: P. Carayon (France)

Posters

0437	0446	0459	0488
0444	0450	0463	0492
0445	0454	0470	0496

Haematology

Chair: R. Sierra Amor (Mexico)

Posters

0521	0536	0547	0570
0523	0538	0550	0575
0528	0543	0566	0588

Infectious diseases (acute and chronic)

Chair: C. Knabbe (Germany)

Posters

0648	0656	0668	0675
0651	0660	0672	0676
0655	0667	0673	0692

Liver and gastrointestinal diseases

Chair: F. Ceriotti (Italy)

Posters

0761	0771	0778	0787
0762	0773	0779	0795
0765	0776	0786	0796

Patient and laboratory management

Chair: R. Lichtinghagen (Germany)

Posters

0895	0902	0914	0921
0897	0909	0915	0922
0901	0911	0918	0923

Toxicology, instrumentation and methods, metabolomics

Chair: K. Kappert (Germany)

Posters

1156	1168	1172	1184
1157	1170	1182	1185
1163	1171	1183	1190

Miscellaneous

Chair: P. Sinha (Austria)

Posters

1242	1250	1257	1275
1243	1254	1258	1292
1247	1256	1260	1297

13:00 - 14:00

INDUSTRY-SPONSORED WORKSHOPS

HALL 8

TESTING FOR VITAMIN D DEFICIENCY: DEFINING AT-RISK POPULATIONS



13:00 Testing for vitamin D deficiency: Defining at-risk populations
To be defined

HALL 14.2

CLINICAL AND ECONOMIC ADVANCES IN PROSTATE CANCER DIAGNOSIS

Chair: A. Semjonow (Germany)



13:00 Prostate cancer detection: The patient's view
V. Griesser (Switzerland)

13:20 Improving PSA – based prostate cancer detection with the Prostate Health Index (phi)
C. Stephan (Germany)

13:40 Quantifying the economic value of phi
J. Minken (USA)

HALL 7

IMPORTANCE OF BIOMARKERS IN OPTIMISING THE TREATMENT OF PATIENTS WITH HEART AND KIDNEY DISEASE

Chair: P. Venge (Sweden)



13:00 Introduction
P. Venge (Sweden)

13:10 ARCHITECT sensitive Troponin and clinical outcome in patients with suspected acute coronary syndrome
N. Mills (United Kingdom); S. Walker (United Kingdom)

13:34 NGAL for the early identification of renal complications in the Emergency Department
K. Schmidt-Ott (Germany)

13:00 - 14:00

INDUSTRY-SPONSORED WORKSHOPS

HALL 4/5

TRUST BUT VERIFY: HOW TO EVALUATE HAEMATOLOGY SYSTEMS

Chair: O. Hauss (Germany)

- 13:00** Trust but verify: How to evaluate haematology systems
S.J. Machin (United Kingdom)



HALL 9

THE VALUE OF IMPROVED WORKFLOW SOLUTIONS

Chair: M. Plebani (Italy)

- 13:00** Impacting Laboratory Workflow with Adaptable Design
T. Galloway (USA)
- 13:30** A User's Experience
J. Bruemmer (Germany)



HALL 10

IMPACT OF NEW OMICS-PLATFORMS ON BIOMARKER DISCOVERY AND APPLICATIONS

Chair: K. Bindseil (Germany)

- 13:00** Glycanmicroarrays as Diagnostic Tool
P.H. Seeberger (Germany)
- 13:20** Unbiased and targeted Metabolite Profiling Platforms for Biomarker Discovery and Validation
L. Willmitzer (Germany)
- 13:40** Autonomous Biosensors - Technologies that help to bring Biomarkers to the Patient
F.F. Bier (Germany)



14:15 - 15:15

INDUSTRY-SPONSORED WORKSHOPS

HALL 14.2

THE CLINICAL UTILITY OF MULTIPLEX BIOCHIPS FOR THE DETECTION OF MULTIPLE STI'S AND RESPIRATORY PATHOGENS

Chair: P.V. Coyle (United Kingdom)

RANDOX

14:15 The clinical and practical implications of 10-plex Sexually Transmitted Infection (STI) biochip array

P.V. Coyle (United Kingdom)

14:45 Ability of a multiplex biochip array to simultaneously detect up to 8 bacterial respiratory pathogens in a clinical setting

M. Diggle (United Kingdom)

HALL 4/5

SEDIMAX: RECENT AND SIGNIFICANT ADVANCES IN AUTOMATED URINE SEDIMENT EXAMINATION

Chair: G.B.Fogazzi (Italy)

A.MENARINI
diagnostics

14:15 New features of sediMAX technology

G.Bayer (Hungary)

14:35 Can significant bacteriuria be detected by sediMAX ?

R.Falbo (Italy)

14:55 The identification by sediMAX of the clinically relevant urine sediment particles

G.B.Fogazzi (Italy)

14:30 - 16:30

PARALLEL SESSIONS

Symposium 5**HALL 1****FROM BENCH TO BEDSIDE IN AUTOIMMUNITY**

Chairs: F. Alvarez Menéndez (Spain), U. Sack (Germany)

- 14:30** Antiphospholipid syndrome: Pathogenesis
T. Koike (Japan)
- 14:55** Novel strategies for the treatment of rheumatoid arthritis
S. Gay (Switzerland)
- 15:20** The many challenges of autoantibody testing
J. Sheldon (United Kingdom)
- 15:45** New clinical aspects in rheumatoid arthritis - Guideline based management
J.S. Smolen (Austria)
- 16:10** Profiling of antiphospholipid antibodies – Association with cerebrovascular events in antiphospholipid syndrome
D. Roggenbuck (Germany)
- 16:20** The Anti-CCP antibodies correlated with rheumatoid factor, erythrocyte sedimentation rate and disease activity index in rheumatoid arthritis
IP. Guzmán-Guzmán (Mexico)

Symposium 6**HALL 3****DIABETES MELLITUS**

Chairs: A. Gronowski (USA), E. Schleicher (Germany)

- 14:30** IFCC standardised HbA1c: Should the world be as one?
W. G. John (United Kingdom)
- 14:55** Genetics of type 2 diabetes - Are we getting any closer?
A. Rosengren (Sweden)
- 15:20** HbA1c in the diagnosis of diabetes: Opportunities and problems
D. Sacks USA)
- 15:45** Molecular and biochemical mechanisms of diabetic complications
P. Gillery (France)
- 16:10** Hemeoxygenase-1 and its metabolic role in the liver
E. Einwallner (Austria)
- 16:20** Urinary 8-hydroxydeoxyguanosine as a biomarker of microangiopathic complications in Type 2 diabetic patients
S.H.Atef (Egypt)

14:30 - 16:30

PARALLEL SESSIONS

Workshop 2

HALL 8

14:30-16:00

EMERGING INFECTIONS AT AFCB COUNTRIES

Chairs: W. ElGarf (Egypt)



- 14:30** Antimicrobial resistance:
An emerging public health problem
Z. Hallaj (Egypt)
- 15:00** Malaria: A global threat
E.T. Khalil (Sudan)
- 15:30** Tuberculosis: Persisting problem in Arab countries
G. Shannan (Syria)

Symposium

HALL 7

HOW TO ASSESS THE CLINICAL EFFECTIVENESS OF LABORATORY TESTS?

Chairs: A.R. Horvath (Australia), A. StJohn (Australia)



- 14:30** Industry and regulatory perspectives: Clinical evidence for IVDs
J. Rueda (Belgium)
- 15:00** Laboratory perspectives: Testing a test - phases of biomarker evaluation
A.R. Horvath (Australia)
- 15:30** Epidemiologic and economic perspectives: Evaluating the effectiveness and costs of monitoring
P. Bossuyt (The Netherlands)
- 16:00** Clinical perspectives: Clinical effectiveness of self-monitoring oral anticoagulant treatment
C. Heneghan (United Kingdom)

14:30 - 16:30

PARALLEL SESSIONS

Symposium**HALL 9****LABORATORY MEDICINE - QUO VADIS?****CONDITIONS, STRUCTURES AND DEVELOPMENTAL TRENDS IN EUROPE**

Chair: J. Aufenanger (Germany), M. Müller (Germany)

**14:30** Concentration in German laboratory medicine – Where are we headed?*M. Müller* (Germany)**15:00** Laboratory medicine as a medical discipline – Is the physician in the laboratory (in)dispensable?*R. Klakow-Franck* (Germany)**15:30** Laboratory medicine in competition – The Swiss experience*A.R. Huber* (Switzerland)**16:00** France on its way to centralised laboratory diagnostics*B. Wiegel* (Germany)*Simultaneous translation from German to English will be provided***Interactive Session 1****HALL 10****14:30-16:00****PITFALLS IN THE HEMOSTASIOLOGIC DIAGNOSTICS:
CLINICAL CASES**

Chair: A. Griesmacher (Austria)

14:30 Current aspects and future trends in the analysis of blood coagulation*K.T. Preissner* (Germany)**14:52** New anticoagulants and routine coagulation tests*A. Haushofer* (Austria)**15:14** Two puzzling cases*B. Lämmle* (Switzerland)**15.36** General case report*G. Weigel* (Austria)*A voting system will be provided.**This session will allow delegates to interact with the speaker and make the session an active one!*

15:30 - 16:30

INDUSTRY-SPONSORED WORKSHOPS

HALL 14.2

ENHANCING PATIENT CARE IN THE CHALLENGING DIAGNOSTIC ARENA IN EUROPE

How to face European Healthcare and Diagnostics Challenges with process solutions that maximize clinical laboratory cost efficiencies

Chair: *M.Naraghi* (Germany)

15:30 Introduction and welcome

E. Hanna

15:35 Healthcare economics challenges in diagnostics

M.Naraghi (Germany)

15:55 Implementation of lean process solutions to improve Clin Lab cost efficiencies

A. Lusack (United Kingdom)

Ortho Clinical Diagnostics
a  company

HALL 4/5

WORKFLOW OPTIMISATION BY FRONT AND BACK END AUTOMATION IN THE DIAGNOSTIC LABORATORY

Chair: *L. Binder* (Germany)

15:30 Company presentation and product portfolio for laboratory automation

R. Rest (Germany)

15:40 Front end automation at a university laboratory

L. Binder (Germany)

16:05 Automation at a large US reference laboratory

C. Hawker (USA)

 **SARSTEDT**

16:45 - 17:45

INDUSTRY-SPONSORED WORKSHOPS

HALL 8**THERAPEUTIC DRUG MONITORING IN CLINICAL DIAGNOSTICS-
FROM RESEARCH TO ROUTINE**

Chair: C. Halter (Germany)



16:45 Analytical aspects in therapeutic drug monitoring of immunosuppressant drugs
S. Bauer (Germany)

17:15 One TDM-analysis that detects them all: The MassTox® TDM Series
C. Halter (Germany)

HALL 14.2**PERSONALISED THERAPIES FOR CHRONIC HEPATITIS B AND C:
THE LEADING ROLE OF VIROLOGICAL MARKERS**

Chair: A. Stief (Germany)



16:45 Real-time PCR based viral load assay and the
increasing complexity of HCV patients management
S. Sarrazin (Germany)

17:15 Molecular and serological HBV markers as drivers of
individualized patient's care
M. Brunetto (Italy)

16:45 - 17:45

INDUSTRY-SPONSORED WORKSHOPS

HALL 7

**OVARIAN CANCER BIOMARKERS IN THE CLINICAL CONTEXT –
STRATIFICATION AND MONITORING**

Chair: R. Molina (Spain)



16:45 View of an oncologist – The need to stratify
ovarian cancer patients to obtain optimal outcomes

J. Sehouli (Germany)

17:05 Diagnostic value of HE4, CA125 and the ROMA Index in ovarian cancer patients from a
tertiary center

E. Høgdall (Denmark)

17:25 The Role of CA125 in ovarian cancer follow-up

C. Marth (Austria)

HALL 4/5

**HbA1c: NEW BREAKTHROUGH TECHNOLOGY FOR LABORATORIES
FACING A CHANGE OF PARADIGM**

Chair: L. Thomas (Germany)



16:45 HbA1c change of paradigm

A. Mosca (Italy)

17:05 Current HbA1c techniques: what is really being measured

A. Mosca (Italy)

17:25 Next generation of separation method for HbA1c:

First evaluation of the CAPILLARYS™ 2 Flex Piercing HbA1c

P. Gillery (France)

16:45 - 17:45

INDUSTRY-SPONSORED WORKSHOPS

HALL 9

ZENTRALLABOR VS. VERBUNDLABOR

Chairs: J. Kuhn (Germany); K. Richarz (Germany)



HALL 10

USING ACTIVE B12 TO DIAGNOSE VITAMIN B12 DEFICIENCY

Chair: J. Scott (Ireland)

**16:45** The diagnostic accuracy of Active B12 (holotranscobalamin)*J. Scott* (Ireland)**17:15** Outcomes of a multi-centre study and experience with introducing and running Active B12 in the clinical chemistry lab*J. Lindemans* (The Netherlands)

Monday 16 May

CLOSED MEETINGS

8:00-11:00 Room 42

IFCC WG-IANT

Chair: M. Blanes Gonzales

8:00-11:00 Room 44

APFCB Executive Board

8:00-9:00 Room 45

IFCC WG-BMS

Chair: S. Vasikaran

9:00-11:00 Room 48

EFCC C-P and EC4 Foundation Board

Chair: S. Zerah

8:00-11:00 Room 49

EFCC WG-BV

Chair: B. Bartlet

8:00-11:00 Room 13/14

IFCC TF-PG

Chair: R. van Schaik

8:00-11:00 Salon 20

IFCC C-MD

Chair: M. Pazzagli

9:00-11:00 Room 45

DQCLM

Chair: M. Thomas

9:00-11:00 / 14.30-17:30 Room 47

IFCC C-PR

Chair: K. Adeli

9:00-11:00 Salon 19

IFCC WG-AETR

Open Meeting

Chair: R. Bais

11:30-14:00 Room 42

DGKL AG In/Outsourcing

12:00-14:00 Room 45

Analytical harmonization EFCC/AACC

Chair: S. Sandberg

14:30-17:30 Room 42

DGKL WG LC-MS/MS in Laboratory

Chair: M. Vogeser

14:30-17:30 Room 44

EC4 Register Commission

14:30-17:30 Room 45

IFCC C-CLM

Chair: E. Frank

14:30-17:30 Room 48

EFCC C-S

Chair: S. Sandberg

14:30-17:30 Room 49

IFCC C-CMBC

Chair: M. Neumaier

14:30-17:30 Salon 19

IFCC C-RIDL Networking

Chair: K. Ichihara

14:30-17:30 Salon 20

IFCC C-TLM

Open Meeting


Chair: A. Kessler

14:30-17:30 Room 13/14

IFCC WG-SAU and WG-GFRA

Open Meeting

Chairs: N. Greenberg, G. Miller



We Impact Life at Every Stage

At Abbott, we deliver products you can count on to provide superior patient care – across the spectrum of health.

Discovering new and better ways to manage health has driven our work for more than a century. Today, our comprehensive line of products spans the continuum of care – from pharmaceutical therapies and nutritional products to diagnostics and surgical devices – addressing important health needs from infancy to the golden years, and in more ways than ever.

We strive to earn your continued trust by delivering high-quality, reliable products backed by leading-edge science and expertise across a range of health care specialties.

We deliver on our promises by focusing on what matters most: innovative care and a desire to make a meaningful difference in all that we do.



- | | | | | | | |
|-----------------|----------------|----------------|--------------|-----------------|---------------|----------|
| Anesthesia | Cardiovascular | Hematology | Metabolics | Nutrition | Point of Care | Vascular |
| Animal Health | Diabetes Care | Immunology | Molecular | Oncology | Renal Care | Virology |
| Anti-Infectives | Diagnostics | Medical Optics | Neuroscience | Pain Management | Respiratory | |

9:00 - 11:00

PARALLEL SESSIONS

Symposium 7

HALL 1

PHARMACOGENETICS AND PHARMACOGENOMICS

Chairs: U. Tuma (Brazil), R. van Schaik (The Netherlands)

- 9:00** Pharmacogenetics in the treatment of psychiatric diseases
C. Hiemke (Germany)
- 9:25** Pharmacogenetic predictors of drug induced liver injury
M. Pirmohamed (United Kingdom)
- 9:50** The rapidly evolving state of the art in clinical pharmacogenetic applications
M. Linder (USA)
- 10:15** Pharmacogenetics of anti-cancer therapy
R. van Schaik (the Netherlands)
- 10:40** Reduced overall survival of CYP2C19 *2/*2 homozygotes after myeloablative hematopoietic stem cell transplantation
P. Jarolim (USA)
- 10:50** VKORC1, CYP2C9 AND CYP4F2 genetic based algorithm for warfarin dosing. Preliminary results of a prospective Italian study
C.-F. Zambon (Italy)

Year in Review 2

HALL 3

ADVANCES IN CLINICAL CHEMISTRY IN THE FIELD OF NEPHROLOGY AND ENDOCRINOLOGY

Chairs: G. Benga (Romania), J. Delanghe (Belgium)

- 9:00** New markers for acute kidney injury
C. Ronco (Italy)
- 9:30** Beyond creatinine standardisation
J. Delanghe (Belgium)
- 10:00** POCT glucose measurement and its limitations
D. Bruns (USA)
- 10:30** The D-Lightful vitamin D for health
M.F. Holick (USA)

9:00 - 11:00

PARALLEL SESSIONS

Workshop 3**HALL 8****9:00-10:30****OXIDATIVE STRESS IN DIABETES MELLITUS**

Chairs: T. Zima (Czech Republic)

- 9:00** Role of nrf2 and the antistress gene response in countering oxidative stress in diabetes mellitus
P.J. Thornalley (United Kingdom)
- 9:30** Oxidative stress markers in diabetic complications
A. Ceriello (United Kingdom)
- 10:00** Oxidative stress and caloric restriction
J. Skrha (Czech Republic)

Symposium 8**HALL 14.2****INFECTIOUS DISEASES**

Chairs: S. Suerbaum (Germany), R. Tauber (Germany)



- 9:00** Impact of genomics on molecular epidemiology of MRSA
W. Witte (Germany)
- 9:25** Helicobacter pylori – A global carcinogenic pathogen
S. Suerbaum (Germany)
- 9:50** Influenza pandemic, vaccination and pitfalls of communication
S. Becker (Germany)
- 10:15** The fourth dimension: Combining epidemiologic and typing data for the transition from data to knowledge for infectious diseases
D. Harmsen (Germany)
- 10:40** Genotypic prediction of HIV-1 coreceptor tropism from plasma and peripheral blood mononuclear cells in the clinical routine laboratory
J. Berg (Austria)
- 10:50** Leishmania: Probable genetic hybrids between species in Sudanese isolates
S.H. Hassabelgawi (Sudan)

9:00 - 11:00

PARALLEL SESSIONS

Symposium

HALL 7

BIOCHEMICAL ANALYSIS PRIZE – AWARD CEREMONY

Chair: K. Lackner (Germany), U. Walter (Germany)

9:00 Laudatory speeches
K.J. Lackner – President DGKL
J. Thiery – Vice President DGKL



9:20 Award Lectures
J.M. Rothberg (USA)
S. Pääbo (Germany)

10:40 Closing remarks

Simultaneous translation from English to German will be provided



Symposium 9 HALL 4/5
HAEMATOLOGY AND ANEMIA

Chairs: R. Sierra Amor (Mexico), J. Wesenberg (Canada)

9:00 Diagnostic of thalassemia
A. Huber (Switzerland)

9:25 How can hepcidin help us in the diagnosis of iron disorders?
D.W. Swinkels (The Netherlands)

9:50 Hepcidin function and regulation
M. Muckenthaler (Germany)

10:15 Laboratory diagnosis of hereditary spherocytosis
M.J. King (United Kingdom)

10:40 Customizing Sysmex flags for a specific patient population using statistical methods
B.A. Stotler (USA)

10:50 JAK2 V617F promotes expression of oncostatin M in myeloproliferative neoplasms:
A potential link between abnormal JAK-signaling and bone marrow microenvironment
alterations
G. Hörmann (Austria)

9:00 - 11:00

PARALLEL SESSIONS

EMD C-CMBC Symposium HALL 9
BIOBANKING AND LABORATORY MEDICINE: TWO RESOURCES
FOR MODERN HEALTH CARE

Chairs: M. Neumaier (Germany)



- 9:00** Biobanking infrastructures: Networks for future biomedical research and laboratory medicine
M. Neumaier (Germany)
- 9:30** Ethical and bio-legal aspects: Crossborder experiences in Europe
M. Kiehntopf (Germany)
- 10:00** Public health and biobanking – The role of public health genomics
A. Brand (The Netherlands)
- 10:30** The key role of biobanking for the study of complex diseases
M. Ferrari (Italy)

Workshop 4 HALL 10 9:00-10:30
UPDATE ON CARDIAC TROPONIN -
CLINICAL AND LABORATORY ISSUES

Chair: J. Tate (Australia)

- 9:00** A roadmap for cardiac troponin I standardization and traceability
D. Bunk (USA)
- 9:30** The round Robin study for cardiac troponin I - Progress report
J. Tate (Australia)
- 10:00** Clinical use of high-sensitivity troponin assays
H.A. Katus (Germany)

11:30-12:45

PLENARY SESSION

HALL 1

ADVANCES IN CLINICAL AND DIAGNOSTIC IMMUNOLOGY

Chairs: A.R. Horvath (Australia), M.M. Müller (Austria)

11:30

Chronic inflammatory bowel disease – From bench to bedside

M.F. Neurath (Germany)



Markus Neurath is an international leading scientist on the field of immunology and endomicroscopy of the gut who was awarded with well-known research prizes for his work, e.g. the UEGF Research Prize. His research deals with the immunologic and molecular mechanisms in the pathogenesis of inflammatory bowel diseases and GI-cancer.

11:55

Integrative genomic analysis of T cell immunity in humans

W.N. Haining (USA)



Dr. Haining is a physician-scientist who received his undergraduate and medical degree from Oxford University, UK. He moved to the United States in 1993 to complete medical training in Pediatrics at Children's Hospital, Boston, and subsequently in Pediatric Hematology/Oncology at Dana-Farber Cancer Institute. After post-doctoral research at MIT and Dana-Farber Cancer Institute, he was appointed to the faculty as Assistant Professor of Pediatrics in 2007 in the Department of Pediatric Oncology. Dr. Haining's research focuses on understanding why the immune system fails in cancer and chronic viral disease.

His studies have integrated cutting edge genomics and computational biology approaches with cellular immunology to identify the critical molecular mechanisms that impair the T cell response to HIV and tumor cells. His work has provided novel therapeutic targets to revive defective HIV-specific T cell immunity and have laid the groundwork for the broader understanding of the immunologic genome.

12:20

Gene-environment interaction in chronic inflammatory disease

H. Renz (Germany)



The central research area of Harald Renz is the role of the adaptive immune system in the pathogenesis of allergy and asthma. He is internationally recognized for his work on the role of T-cell effector subsets on initiation, progression and remodelling of chronic inflammatory disease, particularly in bronchial asthma and atopic dermatitis. He was among the first to demonstrate that T-cells play an important role in the development of airway hyperreactivity in asthma and trigger the chronic inflammatory response in this condition. He pioneered the development of disease-related animal models which mimic several important hallmarks of

the disease, including initiation, progression and remodelling. In terms of disease-initiation, he provides important contributions to the "hygiene hypothesis". He is serving as immunological study site in several international research consortia and proved the importance of early life events for programming of the immune system. His work offers novel cellular and molecular explanation for the role of microbes in preventing the development of allergic conditions even in a transgenerational manner.

13:30-14:30**POSTER WALKS****Poster Area**

In order to encourage discussions, poster walks will be held on Monday, Tuesday, and Wednesday from 13:30 to 14:30. The author of the selected posters is asked to be by his/her poster panel from 13:30 to 14:30. Each author will have up to three minutes to present the poster.

The chairman selected for each poster walk will guide the walk and chair the discussion.

All delegates wishing to attend poster walks must be at the first poster panel (see poster-panel code) at 13:30.

Ageing

Chair: M. Walter (Germany)

Posters

0001	0004	0007	0010
0002	0005	0008	
0003	0006	0009	

Autoimmune disease

Chair: J. Lopez (Malaysia)

Posters

0021	0030	0035	0040
0025	0033	0036	0042
0027	0034	0038	0054

Endocrinology

Chair: M. Kiehntopf (Germany)

Posters

0103	0125	0144	0152
0116	0128	0146	0157
0118	0142	0149	0159

Cardiovascular disease

Chair: C. Knabbe (Germany)

Posters

0449	0453	0493	0498
0451	0464	0494	0501
0452	0491	0495	0503

Haematology

Chair: L. Thomas (Germany)

Posters

0520	0533	0579	0583
0524	0560	0580	0584
0527	0563	0582	0587

Haemostasis

Chair: U. Walter (Germany)

Posters

0595	0604	0617	0627
0597	0606	0619	0629
0598	0611	0621	0634

Kidney disease

Chair: F. H. Perschel (Germany)

Posters

0696	0705	0724	0741
0700	0713	0730	0745
0703	0718	0739	0755

Molecular diagnostics

Chair: K. Psarra (Greece)

Posters

0798	0806	0815	0825
0802	0809	0817	0831
0805	0814	0821	0834

Neurological diseases(acute and chronic)

Chair: G. Sypniewska (Poland)

Posters

0836	0844	0847	0858
0839	0845	0850	0859
0841	0846	0855	

Patient and laboratory management

Chair: P. Sinha (Austria)

Posters

0890	0896	0900	0910
0891	0898	0906	0917
0892	0899	0907	0920

Pharmacogenetics/pharmacogenomics

Chair: E. Wieland (Germany)

Posters

0925	0930	1028	1064
0926	1014	1037	1069
0928	1015	1038	1072
0929	1025	1063	1074

Vitamins

Chair: R. Bais (Australia)

Posters

1215	1218	1225	1231
1216	1219	1226	1234
1217	1222	1228	1236

Quality assessment, standardization

Chair: W. Herrmann (Germany)

Posters

1014	1028	1063	1072
1015	1037	1064	1074
1025	1038	1069	

13:00 - 14:00

INDUSTRY-SPONSORED WORKSHOPS

HALL 8

INCREMENTAL VALUE OF H-FABP IN AN ERA OF HIGHLY SENSITIVE TROPONINS

Chair: R. Body (United Kingdom)


 RANDOX

13:00 The diagnostic utility of heart-type fatty acid binding protein in patients with acute coronary syndrome
J. Barth (United Kingdom)

13:30 Heart-fatty acid binding-protein may enable immediate exclusion of acute myocardial infarction in the emergency department
R. Body (United Kingdom)

HALL 14.2

FROM CLINICAL CHEMISTRY TO MOLECULAR DIAGNOSTICS: INNOVATIVE SOLUTIONS FOR LABORATORY AUTOMATION AND ORGANISATION

Chair: J. Wood (United Kingdom)


 BECKMAN
 COULTER
 We're better together

13:00 Reaching optimal efficiency in a high volume laboratory
D. Münstermann (Germany)

13:20 AU5800: The new ultra high throughput chemistry analyser – First experience
T. von Schrenck (Germany)

13:40 UniCel DxN, the next generation in clinical molecular diagnostics automation
M. Topham (USA)

HALL 7

LABORATORY DIAGNOSIS OF HEPATITIS C – WHAT ARE LOOKING FOR?

Chair: A. Vockel (Germany)

13:00 Hepatitis C infections – A hidden, but no “occult” disease
J. Izopet (France)

13:30 HCV Antigen – An effective marker to improve HCV diagnostics?
P. Holder (Ireland)


 Abbott
 A Promise for Life

13:00 - 14:00

INDUSTRY-SPONSORED WORKSHOPS

HALL 4/5

TRUST BUT VERIFY: HOW TO EVALUATE HAEMATOLOGY SYSTEMS

Chair: O. Hauss (Germany)

- 13:00** Trust but verify: How to evaluate haematology systems
S.J. Machin (United Kingdom)



HALL 9

FOCUS ON NEW DIAGNOSTIC STRATEGIES IN AUTOIMMUNITY

Chair: I. Abreu (Portugal), N. Bizzaro (Italy)

- 13:00** A simplified diagnostic algorithm for celiac disease
E. Tonutti (Italy)
- 13:20** Clinical and diagnostic significance of anti-ENA antibodies
J. Jimenez Alonso (Spain)
- 13:40** A new multiparametric chemiluminescent assay for the screening of ENA antibodies
N. Bizzaro (Italy)



HALL 10

ENHANCING PATIENT CARE IN THE CHALLENGING DIAGNOSTIC ARENA IN EUROPE

Innovative technological platforms and high quality services to enhance productivity in increasingly complex Lab structures

Chair: A. Lusack (United Kingdom)

- 13:00** Introduction and Welcome
A. Lusack (United Kingdom)
- 13:05** Implementation of innovative technological platforms in increasingly complex laboratory structures
H. Baum (Germany)
- 13:30** e-connectivity and remote monitoring center: A user's perspective
P. Howell (United Kingdom)



14:15 - 15:15

INDUSTRY-SPONSORED WORKSHOPS

HALL 14.2**NEW HORIZONS IN CELLULAR ANALYSIS**

Chair: R. Simon (Switzerland)

- 14:15** Volume, conductivity and scatter properties of leukocytes (VCS Technology) is a highly sensitive and specific predictor of blood culture proven neonatal sepsis
M. Bhargava (India)
- 14:35** Is that the microscope WBC differential count has a future in a hematology lab: the benefits of HematoFlow™ concept
O. Pradier (Belgium)
- 14:55** Anemia – New insights
R. Simon (Switzerland)

**HALL 4/5****DIAGNOSTIC AND CLINICAL IMPORTANCE OF MEASURING VITAMIN D TOTAL**

Chair: P. Sibley (United Kingdom)

- 14:15** Technical and Clinical Aspects
M. Vogeser (Germany)
- 14:40** Multicenter Study of a New Assay on Centaur XP
W. Fraser (United Kingdom)

The Siemens logo, consisting of the word 'SIEMENS' in a bold, teal, sans-serif font.

14:30 - 16:30

PARALLEL SESSIONS

Symposium 10

HALL 1

DIAGNOSTIC USE AND VALUE OF FUNCTION TEST IN ENDOCRINOLOGY

Chairs: P. Carayon (France), L. Thienpont (Belgium)

- 14:30** Molecular genetic work up for thyroid and parathyroid diseases
F. Raue (Germany)
- 14:55** Diagnostic workup of primary aldosteronism
M. Stowasser (Australia)
- 15:20** Vitamin D: Clinical relevance, analytical issues
E. Cavalier (Belgium)
- 15:45** Hormonal changes after gastric surgery and obesity interventions
C. Le Roux (United Kingdom)
- 16:10** Genetic determinants of serum testosterone concentrations in men
R. Haring (Germany)
- 16:20** Expression of a subset of microRNAs in clinically non-functioning pituitary adenomas correlates with tumor size
H. Butz (Hungary)


Symposium 11

HALL 3

POINT OF CARE TESTING - PRACTICAL ASPECTS

Chairs: M. Klouche (Germany), K. Pulkki (Finland)

- 14:30** Management of POCT testing program in a teaching hospital
D. Rogic (Croatia)
- 14:55** Update on current and developing POC applications with a global and emerging country focus
B. Goldsmith (USA)
- 15:20** The operator is key in delivering quality in POC
I. Watson (United Kingdom)
- 15:45** Designing a Quality POCT Program using CLSI documents
L.A. Wyer (USA)
- 16:10** Effect of marked fluctuations in haematocrit on point of care blood glucose systems
G. Creed (United Kingdom)
- 16:20** Impact of analytical performance of point of care (POCT) blood glucose meters on application of a 'tight glycaemic control' (TGC) protocol in an intensive care unit setting
M. Ryan (United Kingdom)



14:30 - 16:30

PARALLEL SESSIONS

Workshop 5**HALL 8****14:30-16:00****LESSONS FROM THE ASIAN - PACIFIC MULTICENTER REFERENCE INTERVAL STUDY**

Chairs: K. Ichihara (Japan)



14:30 Study design: Strategy for collaboration in the definition of reference intervals

K. Ichihara (Japan)

15:00 Statistical considerations in the generation of reference intervals

J. Boyd (USA)

15:30 Obtaining reference intervals traceable to reference measurement systems

M. Panteghini (Italy)

Symposium**HALL 7****QUALITY MANAGEMENT ACCORDING TO THE GERMAN RILIBAEK: AN INTERNATIONAL PERSPECTIVE**

Chair: W. Vogt (Germany), B. Wiegel (Germany)



14:30 German Medical Associations Directive for Quality Assurance for Medical Laboratory tests, history and last issues

W. Vogt (Germany)

15:00 Quality management and quality assurance in Italian medical laboratories

M. Ogriseg (Italy)

15:30 Quality management and quality assurance in Austrian medical laboratories

M. Hubmann (Austria)

16:00 Root mean square of measurement deviation: a new approach in German Medical Associations Directive for Quality Assurance for Medical Laboratory tests

R. Macdonald (Germany)

Simultaneous translation from German to English will be provided



14:30 - 16:30

PARALLEL SESSIONS

Symposium

HALL 9

ACCREDITATION SHOULD BE FOCUSED ON MORE THAN WELL ORGANIZED EXAMINATIONS WITH THE LABORATORY

Chairs: C. Giroud (France), R. Jansen (the Netherlands)



- 14:30** IVD Directive 98/79/CE in relation to ISO 15189
J.C. Libeer (Belgium)
- 15:00** Influence of pre-examination aspects on result's validity –
Are ISO 15189 requirements sufficient and clear?
L. Sprongl (Czech Republic)
- 15:30** ISO 15189: Coverage of validation of results and post-examination aspects:
Is this sufficient?
S. Zerah (France)
- 16:00** The specific roles of assessors during accreditation and beyond
W. Huisman (The Netherlands)

Workshop 6

HALL 10

14:30-16:00

THE 2009 INFLUENZA PANDEMIC - LESSONS LEARNED

Chair: M. Pilonetto (Brazil)

- 14:30** The 2009 influenza pandemic - The experience in the southern hemisphere
A. Kelso (Australia)
- 15:00** Impact of pandemic A/H1N1 virus mutations on drug resistance and virulence
G. Boivin (Canada)
- 15:30** The role of pathogenic immune complexes in severe disease caused by
pandemic influenza
F.P. Polack (Argentina)

15:30 - 16:30

INDUSTRY-SPONSORED WORKSHOPS

HALL 14.2**NEXT GENERATION IN CARDIAC BIOMARKERS: LABORATORY MEDICINE'S CONTRIBUTION TO INDIVIDUALIZED TREATMENT IN ACS AND HEART FAILURE**

Chair: S. Rougale (France)

**15:30** Troponin T high sensitive : Applying the guidelines to hospital's daily life*H. Katus (Germany)***15:50** Future calls : Can GDF 15 be added value to ACS treatment?*K.C. Wollert (Germany)***16:10** NT-pro BNP guided heart failure therapy*J. Januzzi (USA)***HALL 4/5****THE CLINICAL UTILITY OF REFLEX URINE CULTURES BASED ON URINALYSIS AND AUTOMATED URINE MICROSCOPY USING THE IQ200 WORKSTATION****15:30** The clinical utility of reflex urine cultures based on urinalysis and automated urine microscopy using the IQ200 workstation*S. Riedel (USA)*

16:45 - 17:45

INDUSTRY-SPONSORED WORKSHOPS

HALL 8

THE "LEAN" ALTERNATIVE

Chair: S. Rougale (France)



16:45 Lean principles and applications to healthcare

M. Chomyn (Germany)

17:15 Practical applications of lean in UK hospital laboratory

M. Fottles (Germany)

HALL 14.2

EFFICIENT LAB ORGANIZATION FROM PRE- TO POST ANALYTIC

Chair: A. Steif (Germany)



16:45 Overview of Roche Cobas Solutions

C. Brown (Switzerland)

17:05 Optimizing a University Lab

U. Steigerwald (Germany)

17:25 The evolution of a hands-on towards a hands-free laboratory

F. Winnock (Belgium)

HALL 7

AUTOMATION TO ENSURE YOUR LAB'S EFFICIENCY

Chair: G.I. McCurdy (Germany)



16:45 An overview of the benefits of an automated inventory system (RMS)

M. Orth (Germany)

17:15 The implementation and adoption of a Total Laboratory Automation System (APS)

M. Nybo (Denmark)

16:45 - 17:45

INDUSTRY-SPONSORED WORKSHOPS

HALL 4/5

COUNTING THE COST OF THE PREANALYTICAL PHASE

Chair: V. Palicka (Czech Republic), M. Plebani (Italy)



- 16:45** The impact of preanalytical errors on patients' treatment
G. Lippi (Italy)
- 17:05** Understanding the cost of the preanalytical phase in an outpatient setting
G. Soffiati (Italy)
- 17:25** Discovering the opportunity cost of preanalytical errors
M. Nauck (Germany)

HALL 9

NEW HIGH-PERFORMANCE ASSAYS FOR THE DETERMINATION OF FREE LIGHT CHAINS KAPPA AND LAMBDA – ADDING CONSISTENCY TO MONITORING AND SCREENING OF MULTIPLE MYELOMA

Chair: C. Pruemper (Germany)

SIEMENS

- 16:45** Improving determination of FLC Kappa and Lambda by use of Monoclonal Antibodies
H. te Velthuis (The Netherlands)
- 17:15** High sensitivity and specificity of New Nephelometric Assays for FLC Kappa and Lambda in Clinical Practice
R. Hoedemakers (The Netherlands)

HALL 10

CLINICAL MSMS – NEW DEVELOPMENTS IN TODAY'S LABORATORY

Chair: A. Cohen (Denmark)



- 16:45** Mass spectrometry for routine analysis of steroids in clinical samples
A. Cohen (Denmark)
- 17:05** Vitamin D: There is a world beyond the bone, and how to gain a reliable insight
H.J. Roth (Germany)
- 17:25** Standardization and quality of in vitro diagnostic medical devices
L. Thienpont (Belgium)

CLOSED MEETINGS

8:00-11:00 **Room 47**

IFCC WG-HbA2

Chair: R. Paleari

8:00-11:00 **Room 48**

EFCC WG-TE

Chair: AR. Horvath

8:00-9:30 **Salon 11/12**

EFCC WG-DE

Chair: D. Gruson

9:30-11:00 **Salon 11/12**

EFCC C-ET and WG-CPE

Chair: E. Topic

8:00-11:00 **Room 49**

IFCC C-MD

Chair: M. Pazzagli

9:00-10:00 **Room 45**

EFCC WG-TFG PA

Chair: A. Simundic

9:00-11:00 **Room 44**

ISAB Euromedlab Milano 2013

Chair: M. Panteghini

10:00-13:00 **Room 45**

EFCC C-PPR

Chair: A. Wootton

10:30-11:30 **Room 43**

Bergmeyer Conference Steering Committee Meeting

Chair: I. Young

11:00-16:30 **Room 42**

DGKL Division Molecular Diagnostics

Chair: M. Neumaier

11:30-14:00 **Room 44**

ISC Worldlab Istanbul 2014

Chair: N. Ozer

13:00-15:00 **Room Schönefeld**

DGKL Executive Committee

14:00-17:00 **Salon 11/12**

IFCC TF-YS - Open Meeting

Chair: D. Gruson

14:30-16:00 **Room 43**

IFCC Corporate Members

Chair: T. Brinkmann

14:30-17:00 **Room 44**

IFCC National Societies Editors & Publishers

Chair: E. Delvin, E. Jacobs

14:30-17:30 **Room 45**

IFCC C-RSE

Chair: F. Ceriotti

14:30-17:30 **Room 47**

IFCC C-EBLM

Chair: R. Christenson

14:30-17:30 **Room 48**

IFCC WG-SCC

Chair: A. Grubb

14:30-17:30 **Room 49**

EFCC WG-G

Chair: W. Oosterhuis

17:00-18:30 **Room 43**

DGKL Meeting Members



Incomparable performance in Autoimmunity



The chemiluminescence-based **Zenit RA** analyzer meets laboratory needs and provides the operator with:

- **Extreme flexibility** (up to 15 immunoassays on board; continuous access to samples, reagents consumables and parts)
- **Rapid analysis** (first result within 25 minutes; throughput: 70 tests/hour)
- **Full traceability** (barcode reading for all reagents and samples; continuous control of reagent levels; quality control based on Levey-Jenning & Westgard charts)



More ways to transform laboratory workflow.

Exceeding expectations for capacity, performance and quality at El Poniente Hospital.

“With a workload that has doubled in five years, we needed to improve sample management and laboratory procedures to keep pace with demand. By partnering with Beckman Coulter, we automated 90 percent of our manual test processes, improving our ability to provide physicians with timely and consistent results.

El Poniente Hospital is well positioned to support the region’s healthcare structure – helping to advance the quality of medical treatment and patient care to all who live in the area we serve.” – Dr. Cristóbal Avivar, Director of the Integrated Biotechnology Management Area, El Poniente Hospital, El Ejido, Almeria, Spain.

Find out more about how Beckman Coulter can help you improve performance in your laboratory at IFCC-WorldLab and EuroMedLab 2011.

Visit us at
**IFCC-WorldLab and
 EuroMedLab 2011**
 Booth No. 16-01, Hall 16
beckmancoulter.com/IFCC2011

Blood Banking Centrifugation Chemistry Flow Cytometry Hematology Hemostasis
 Immunoassay Information Systems Lab Automation Molecular Diagnostics Rapid Diagnostics



9:00 - 11:00

PARALLEL SESSIONS

Symposium 12**HALL 1****BIOMARKERS IN ACUTE AND CHRONIC BRAIN DISEASES**

Chairs: R.N. Martins (Australia), G. Sypniewska (Poland)

- 9:00** Dissecting Alzheimer's disease: Is AD pathology as a cause or a consequence?
G. Casadesus (USA)
- 9:25** Multiple sclerosis
A.H. Cross (USA)
- 9:50** Identifying blood biomarkers to improve the management of stroke
W. Whiteley (United Kingdom)
- 10:15** S100B protein: A screening tool for the diagnosis of minor head injury
J.L. Beaudeau (France)
- 10:40** Evaluation of the new Marburg cerebrospinal fluid (CSF) model with human spondylopathies
A. Dorn-Beineke (Germany)
- 10:50** Prostatic acid phosphatase (PAP) in neurotransmission
P. Vihko (Finland)

Year in Review 3**HALL 3****DEVELOPMENTS IN CLINICAL LABORATORY PRACTICE**

Chairs: M. Plebani (Italy), I. Rydén (Sweden)

- 9:00** Translational medicine: The case of laboratory medicine
M. Plebani (Italy)
- 9:30** Risk management in the pre-analytical phase
G. Lippi (Italy)
- 10:00** Risk analysis of the analytical testing process
J. Westgard (USA)
- 10:30** Reference values and beyond
F. Ceriotti (Italy)

9:00 - 11:00

PARALLEL SESSIONS

Workshop 7

HALL 8

9:00-10:30

CLINICAL PHARMACOGENETICS

Chairs: M. Pirmohamed (United Kingdom)

- 9:00** CYP2D6 Genotyping to guide use of tamoxifen in breast cancer
K. Weck (USA)
- 9:30** Pharmacogenetics of coumarin
J. Oldenburg (USA)
- 10:00** Can drug induced liver injury be predicted by pharmacogenetics?
T. Szekeres (Austria)

Symposium 13

HALL 14.2

PRENATAL AND NEONATAL SCREENING

Chairs: J.J.M. Hicks (USA), K. Kohse (Germany)

- 9:00** Pre-eclampsia: Genetic and epigenetic aspects
C.B.M. Oudejans (The Netherlands)
- 9:25** An update on antenatal screening for Down's syndrome
N. Wald (United Kingdom)
- 9:50** Circulating cell-free fetal DNA in maternal plasma: Prospects for non-invasive prenatal assessment of fetal aneuploidies
D. van den Boom (USA)
- 10:15** Recommendations in prenatal screening in the world and connections to other diseases like thyropathy
T. Zima (Czech Republic)
- 10:40** Automated assays for sVEGF-R1, PIGF, Inhibin-A and PAPP-A as an aid in early prediction of preeclampsia : preliminary results from a prospective clinical study in a general population
V. Tsatsaris (France)
- 10:50** First-trimester risk calculation for trisomy 13, 18, and 21: Comparison of the screening efficiency between two self-developed programs and astraia software
S. Sørensen (Denmark)

9:00 - 11:00

PARALLEL SESSIONS

Symposium**HALL 7****STANDARDIZATION IN MOLECULAR DIAGNOSTICS**

Chairs: I. Young (United Kingdom)



- 9:00** The need for standardization in molecular diagnostics
M. Pazzagli (Italy)
- 9:30** Standardization in molecular diagnostics: Definitions and uses of nucleic acid reference materials
D. Payne (USA)
- 10:00** The IFCC network of molecular diagnostic centres
F. Rousseau (Canada)
- 10:30** The pharmacogenetics reference laboratory: An IFCC molecular diagnostic center in action
R. van Schaik (The Netherlands)

Symposium 14**HALL 4/5****ALLERGY DIAGNOSTICS**

Chairs: C.W.K. Lam (Hong Kong), J. Lopez (Malaysia)

- 9:00** Emerging concepts in individualized therapy of atopic dermatitis
T. Bieber (Germany)
- 9:25** Component-based diagnostics - recombinant allergens as diagnostic tools
R. Valenta (Austria)
- 9:50** Carbohydrate allergens
T.A.E. Platts-Mills (USA)
- 10:15** The role of in vitro tests in the diagnosis of food allergy
T. Werfel (Germany)
- 10:40** Components-array technology diagnostic, a step forward in the study of the sensitization profile of allergic patients
J.M. Acedo (Spain)
- 10:50** *Recovery*ELISA - A newly developed immunoassay for measurement of therapeutic antibodies (MAb) and the target antigen during antibody therapy
G. Becher (Germany)

9:00 - 11:00

PARALLEL SESSIONS

Symposium

HALL 9

DEVELOPMENT OF A TRANSCRIPTOMIC, PROTEOMIC AND METABOLOMIC DATABASE FOR HUMAN BLOOD CELLS

Chair: G. Schmitz (Germany), C. Wagener (Germany)



- 9:00** Problems and solutions for consolidated blood cell proteome analysis
H. E. Meyer (Germany)
- 9:30** A data storage and retrieval system for across-Omics data integration in eukaryotic systems
K. Helsen (Belgium)
- 10:00** The proteome of resting and activated platelets
R. Zahedi (Germany)
- 10:30** Transcriptomics, proteomics and lipidomics from megakaryopoiesis to platelet senescence
G. Schmitz (Germany)

Simultaneous translation from German to English will be provided



Workshop 8

HALL 10

9:00-10:30

MOLECULAR DIAGNOSIS OF INFECTION

Chair: M. Tavora Mira (Brazil)

- 9:00** Molecular diagnosis of tuberculosis
E. Domann (Germany)
- 9:30** Challenges of molecular diagnosis - The leprosy model
V. Vissa (USA)
- 10:00** Molecular diagnosis of viral infections: Arboviruses and rodent-borne viruses
L. Moraes Figueiredo (Brazil)

11:30-12:45

PLENARY SESSION

HALL 1

THE BRAIN: BIOLOGICAL AND CEREBRAL DISEASES

Chairs: R. Tauber (Germany), I. Young (United Kingdom)

11:30

Alzheimer's disease: From molecular pathology to diagnosis and treatment approaches*R.N. Martins* (Australia)

Professor Ralph Martins' career in Alzheimer's disease has spanned 25 years and resulted in over 200 publications in mid to high impact journals. He established the McCusker Foundation for Alzheimer's Disease Research. He brought together researchers from Western Australian universities, hospitals and aged care providers to establish the Centre of Excellence for Alzheimer's Disease Research of which he is director. With Professors Colin Masters and David Ames, he was successful in obtaining a CSIRO Flagship grant to identify early diagnostic markers of AD. He founded the Western Australian biotech company Alzhyme to develop anti-amyloid drugs for Alzheimer's Disease. This has allowed Alzhyme to take a lead compound from concept to successful animal trials in 4 years.

11:55

Biomarkers in multiple sclerosis*M. Comabella* (Spain)Education/Training

1990 University of Barcelona - MD Medicine
1995 Hospital Vall d'Hebron - Specialist Neurology

Scientific Training and Experience

1992 - 1995 Resident in Neurology. Hospital Vall d'Hebron, Barcelona, Spain
1996 - 1998 Research fellowship in Neuroimmunology. Harvard Medical School, Center for Neurologic Diseases - Brigham and Women's Hospital, Boston, US
1999 - 2001 Research and Clinical Neurologist. Hospital Vall d'Hebron

Present Position

Research and Clinical Neurologist. Deputy Director Neuroimmunology lab. Clinical Neuroimmunology Unit. Hospital Vall d'Hebron. Barcelona, Spain

12:20

Mechanisms of neurotoxicity and neurodegeneration in prion diseases*A. Aguzzi* (Switzerland)

A. Aguzzi is professor and director of the Institute of Neuropathology at the University of Zurich. His research career has focused entirely on prions, exploring how they damage brain cells, why they accumulate in lymphoid organs, and how they reach the brain after entering the body from peripheral sites. He is the Founder and Director of the Swiss National Reference Center for Prion Diseases, and is on the Board of Governors of the Swiss Federal School of Technology. He has developed and patented several diagnostic and therapeutic methods in the field of transmissible spongiform encephalopathies. He is an adviser to the British, Italian, and Swiss government on spongiform encephalopathies. Among other honors, Dr. Aguzzi has won 2009 the Antonio-Feltrinelli Prize in Rome, as well as the medal of the European Molecular Biology Organization (EMBO).

13:30-14:30

POSTER WALKS

Poster Area

In order to encourage discussions, poster walks will be held on Monday, Tuesday, and Wednesday from 13:30 to 14:30. The author of the selected posters is asked to be by his/her poster panel from 13:30 to 14:30. Each author will have up to three minutes to present the poster.

The chairman selected for each poster walk will guide the walk and chair the discussion.

All delegates wishing to attend poster walks must be at the first poster panel (see poster-panel code) at 13:30.

Cardiovascular disease

Chair: J. Tate (Australia)

Posters

0187	0200	0224	0258
0195	0211	0246	0291
0198	0220	0249	0302

Diabetes mellitus and metabolic syndrome

Chair: F. H. Perschel (Germany)

Posters

0336	0345	0403	0417
0338	0388	0413	0424
0340	0399	0415	0426

Genetic disease

Chair: B. Hoppe (Germany)

Posters

0507	0510	0513	0516
0508	0511	0514	0517
0509	0512	0515	0519

Infectious diseases (acute and chronic)

Chair: M. Walter (Germany)

Posters

0636	0641	0646	0654
0638	0642	0647	0677
0640	0643	0653	0687

Kidney disease

Chair: N. Ozer (Turkey)

Posters

0694	0706	0710	0719
0695	0707	0711	0754
0702	0709	0714	0760

Liver and gastrointestinal diseases

Chair: B. Gouget (France)

Posters

0766	0770	0775	0783
0768	0772	0777	0785
0769	0774	0780	0788

Neurological diseases (acute and chronic)
Chair: J.-L. Beaudeau (France)
Posters

0835	0843	0851	0854
0837	0848	0852	0856
0838	0849	0853	

Paediatric clinical chemistry
Chair: K. Kohse (Germany)
Posters

0870	0873	0878	0885
0871	0874	0879	0887
0872	0876	0884	0888

Point of care testing
Chair: K. Pulkki (Finland)
Posters

0933	0937	0948	0956
0934	0938	0953	0958
0936	0947	0954	0963

Pregnancy and neonatology
Chair: K. Tomberg (Estonia)
Posters

0974	0980	0983	0991
0977	0981	0985	1009
0978	0982	0987	1011

Quality assessment, standardization
Chair: C.B.M. Oudejans (The Netherlands)
Posters

1019	1026	1041	1055
1020	1035	1049	1060
1024	1036	1051	1061

Technology, instrumentation and methods, metabolomics
Chair: O. Wagner (Austria)
Posters

1078	1098	1117	1147
1084	1103	1133	1149
1090	1109	1140	1151

Technology, instrumentation and methods, metabolomics
Chair: E. Wieland (Germany)
Posters

1080	1118	1127	1145
1085	1119	1128	1146
1100	1122	1143	1150

Traceability and standardization
Chair: K. Ichihara (Japan)
Posters

1194	1197	1200	1204
1195	1198	1201	1207
1196	1199	1203	1208

13:00 - 14:00

INDUSTRY-SPONSORED WORKSHOPS

HALL 8

THE USE OF MULTIPLEX ASSAYS FOR DETERMINING PREDISPOSITION TO HYPERTENSION

Chair: J. Lamont (United Kingdom)



- 13:00** The use of multiplex assays for determining predisposition to hypertension
S. Visvikis-Siest (France)

HALL 14.2

NOVEL MARKERS IN REPRODUCTIVE ENDOCRINOLOGY

Chair: J. Barth (United Kingdom)



- 13:00** Anti-Müllerian hormone:
A marker of ovarian reserve
R. Anderson (United Kingdom)
- 13:20** Anti-Müllerian hormone: Does it have a role in polycystic ovarian syndrome?
J. Barth (United Kingdom)
- 13:40** New biomarker of pre-eclampsia
V. Tsatsaris (Paris)

HALL 7

VITAMIN D AND B12 – IMMUNOASSAYS IN PREVENTIVE MEDICINE

Chair: S. Lorenz



- 13:00** Recommendations on Vitamin D testing and an analytical evaluation of the ARCHITECT 25-OH Vitamin D assay
E. Cavalier (Belgium)
- 13:30** Clinical implications and methods to detect early development of Vitamin B 12 deficiency?
W. Hermann (Germany)

13:00 - 14:00

INDUSTRY-SPONSORED WORKSHOPS

HALL 4/5

WORK AREA MANAGEMENT: THE ULTIMATE PRODUCTIVITY TOOL

Chair: O. Hauss (Germany)

- 13:00** Work Area Management: The ultimate productivity tool
A. Henley (United Kingdom), *C. Whittington* (United Kingdom)



HALL 9

 Freelite™ AND Hevylite™ IN MONOCLONAL GAMMOPATHIES:
 IMPROVING DIAGNOSIS, MONITORING AND PROGNOSIS ASSESSMENT

Chair: M.L. Villar (Spain)

- 13:00** Free light chain measurement in serum – Clinical use and laboratory handling
G. Merlini (Italy)
- 13:20** Why serum free light chain testing is critical in patients with renal impairment
C. Hutchison (United Kingdom)
- 13:40** Heavy/Light chain antibodies for monitoring and prognostication in patients with myeloma
A. Bradwell (United Kingdom)



HALL 10

 VITAMIN D DIETARY REFERENCE INTAKES: IMPLICATIONS AND
 SIGNIFICANCE IN CLINICAL PRACTICE

- 13:00** Vitamin D dietary reference intakes: Implications and significance in clinical practice
B. Hollis (USA), *S. Pilz* (Austria), *R. Vieth* (Canada)



14:15 - 15:15

INDUSTRY-SPONSORED WORKSHOPS

HALL 14.2

PERSONALISED HEALTHCARE AS A KEY DRIVER FOR PRESENT AND FUTURE DIAGNOSTIC/THERAPEUTIC STRATEGIES

Chair: A. Stief (Germany)



14:15 Roche strategy for PHC
T. Gutjahr (Switzerland)

14:35 Biomarkers for management of breast cancer and other tumors
J. Rüschoff (Germany)

HALL 4/5

A NEW PROSPECTIVE FOR THE AUTOMATION OF CLINICAL CHEMISTRY TESTING

Chair: C. Kostner (Germany)



14:15 respons[®] 910: A multipurpose clinical chemistry system
R. Schenk (Germany)

14:35 Hands-on experience with respons[®] 910 during external evaluation
M.M. Stratmann (Germany)

14:55 Photometric determination of electrolytes – The alternative to ISE
S.Meyer (Germany)

14:30 - 16:30

PARALLEL SESSIONS

Symposium 15**HALL 1****NEW DEVELOPMENTS IN HAEMOSTASEOLOGY**

Chairs: N. Majkic-Singh (Serbia), U. Walter (Germany)

- 14:30** Coagulation factor XIII deficiency
L. Muszbek (Hungary)
- 14:55** Genetics and epidemiology of thrombophilia
F.R Rosendaal (The Netherlands)
- 15:20** Platelets
U. Walter (Germany)
- 15:45** Monitoring of anticoagulant therapy
B. Lämmle (Switzerland)
- 16:10** Detection of an additional, newly detected polymorphism in the factor V gene with a heterozygous factor V Leiden genotype showing a normal APC-resistance test result
F. Prüller (Austria)
- 16:20** Direct thrombin-inhibitors lead to underestimation of thrombotic risk by influencing functional APC-resistance testing
L. Loacker (Austria)

Symposium 16**HALL 3****CONTRIBUTION OF LABORATORY MEDICINE IN LEUKAEMIA**

Chairs: P. Schuff-Werner (Germany), O. Zinder (Israel)

- 14:30** Acute myeloid leukemia: Molecular diagnostics and MRD
A. Neubauer (Germany)
- 14:55** Identification of prognostic subgroups in acute leukemia by novel phenotypic patterns and MDR assay
J. Kappelmayer (Hungary)
- 15:20** Diagnosis of AML between morphology and next generation sequencing
T. Haferlach (Germany)
- 15:45** Myeloproliferative neoplasia: Diagnostic tools for classification and therapy guidance
J. Westermann (Germany)
- 16:10** A rapid bacterial-based bioluminescent assay for in vitro testing of chemotherapy sensitivity
J.V. Lamont (Ireland)
- 16:20** Endogenous colony growth predicts for a less pronounced molecular response to Imatinib therapy in patients with chronic myeloid leukemia
E. Einwallner (Austria)

14:30 - 16:30

PARALLEL SESSIONS

Workshop 9

HALL 8

14:30-16:00

**WHAT PAPERS WILL BE PREFERRED IN THE FUTURE
RELATED TO LABORATORY MEDICINE?
EDITORS POINT OF VIEW**

Chairs: G. Picheth (Brazil)

14:30 Ethical issues involving publications

J. Delanghe (Belgium)

15:00 Position in your journal about the peer review? Is there any alternative?

M. Plebani (Italy)

15:30 Editors role in improving laboratory science

N. Rifai (USA)

Symposium

HALL 7

A SCIENTIFIC APPROACH TO THE POST-ANALYTICAL PHASE

Chairs: E. Ajzner (Hungary), D. Rogic (Croatia)



14:30 Biological variation data: the need for appraisal of the evidence base

B. Bartlett (United Kingdom)

15:00 Reflective testing - Is there evidence that it is worthwhile and for which clinical problems?

W. Oosterhuis (The Netherlands)

15:30 Post-analytical external quality assessment - A way to assess test requesting and interpretation?

S. Sandberg (Norway)

16:00 Postanalytical errors in lipid & lipoprotein testing

M. Langlois (Belgium)

14:30 - 16:30

PARALLEL SESSIONS

Symposium**HALL 9**
**RESEARCH FUNDING BY THE FOUNDATION OF
PATHOBIOCHEMISTRY AND MOLECULAR DIAGNOSTICS OF
THE DGKL – 10 YEARS ON**

Chair: K. Lackner (Germany), J. Thiery (Germany)



- 14:30** Immunoprofiling of the new variable immunoreceptor of neutrophils in acute systemic inflammation
W. Kaminski (Germany)
- 15:00** Pathogenesis of the antiphospholipid syndrome
N. Prinz (Germany)
- 15:30** Role of protease signalling in vascular disease
B. Isermann (Germany)
- 16:00** Sphingoid bases – A new class of biomarkers?
T. Hornemann (Switzerland)

Simultaneous translation from German to English will be provided

**Interactive Session****HALL 10**
CHALLENGES AT THE CLINICAL INTERFACES

Chair: B. Croal (United Kingdom)

- 14:30** Interpretative paradigm 1: Endocrinology case
D. Freedman (United Kingdom)
- 15:00** Interpretative paradigm 2: Water and electrolytes case
A.R. Horvath (Australia)
- 15:30** Interpretative paradigm 3: Toxicology case
M. Hallworth (United Kingdom)
- 16:00** Interpretative paradigm 4: Diabetes case
E. Kilpatrick (United Kingdom)

A voting system will be provided.

This session will allow delegates to interact with the speaker and make the session an active one!

15:30 - 16:30

INDUSTRY-SPONSORED WORKSHOPS

HALL 14.2

CURRENT AND FUTURE PERSPECTIVES IN DRUGS OF ABUSE
SCREENING; THE MULTIPLEX APPROACH

Chair: C. Johnston (United Kingdom)



15:30 The evaluation of the first meprobamate, zopiclone, zolpidem and zaleplon antibodies using biochip multiplexing technology from Randox in plasma, serum and whole blood
J.-C. Alvarez (France)

16:00 Drugs of abuse testing in the routine laboratory; multiplex screening for urine drugs of abuse assays
C. Johnston (United Kingdom)

HALL 4/5

TRACEABILITY AND UNCERTAINTY OF CATALYTIC ACTIVITY
MEASUREMENTS

Chair: F.-J. Gella (Spain)



15:30 Uncertainty of the primary reference systems chemistry system
F. Canalias (Spain)

15:55 Traceability and uncertainty of the values assigned to commercial calibrators
F.-J. Gella (Spain)

16:10 Traceability and uncertainty of the patient measured values
X. Fuentes-Arderiu (Spain)

CLOSED MEETINGS

8:00-9:30 Room 47

EFCC WG-A/ISO

Chair. W. Huisman

8:00-11:00 Room 48

IFCC WG-POCT

Chair. R. Tirimacco

8:00-11:00 Salon 20

IFCC WG-CDT

Chair. F. Schellenberg

9:00-11:00 Room 49

EFCC WG-CS

Chair. J. Delanghe

9:30-11:00 Room 47

EFCC WG-IVD

Chair. JC. Libeer

11:30-14:00 Room 48

DGKL - VDGH Executive Boards

14:30-17:00 Room 47

IFCC WG-LEPS

Chair. M. Plebani

14:30-17:30 Room 48

EFCC WG-CM

Chair. P. Laitinen

14:30-17:30 Room 49

IFCC TF-INTLN

Chair: I. Watson

14:30-17:30 Salon 20

IFCC WG-CDT - Open Meeting

Chair. F. Schellenberg

Wednesday 18 May

9:00 - 11:00

PARALLEL SESSIONS

Symposium 17

HALL 1

NEW STRATEGIES IN MOLECULAR DIAGNOSTIC

Chairs: C. Mannhalter (Austria), K. Psarra (Greece)

- 9:00** DNA melting analysis: From fundamentals to practical applications
C. T. Wittwer (USA)
- 9:25** Quality assurance and quality control in the routine molecular diagnostic laboratory
H. Kessler (Austria)
- 9:50** Next generation sequencing in leukemia diagnostics
A. Kohlmann (Germany)
- 10:15** High throughput qPCR expression profiling, from tissue samples to single cells
M. Kubista (Sweden)
- 10:40** Centrifugal microfluidic platforms for molecular diagnostics
D. Mark (Germany)
- 10:50** Lanthanide chelate complementation in homogeneous well-based four-plex nucleic acid array
U. Karhunen (Finland)

Symposium 18

HALL 3

STANDARDIZATION AND QUALITY CONTROL ISSUES IN EMERGING AND DEVELOPING COUNTRIES

Chairs: G. Shannan (Syria), V. Steenkamp (South Africa)

- 9:00** Analytical quality in the Latin America area
G. Migliarino (Argentina)
- 9:25** Quality assurance programs in Arab countries
F. Harb (Syria)
- 9:50** Standardization and quality control issues in emerging and developing countries
E. Frank (India)
- 10:15** Current status of quality management in laboratory medicine in China
S. Hong (China)
- 10:40** Stabilizing leukocytes enables global implementation of an external quality control for HIV-monitoring
C. Prante (Germany)

9:00 - 11:00

PARALLEL SESSIONS

Workshop 10**HALL 8****9:00-10:30****STANDARDIZATION OF COMPLEX ANALYTE MEASUREMENTS:
THE CLINBIOTRACE PROJECT**

Chairs: H. Parkes (United Kingdom)

- 9:00** The case of human growth hormone: measurement limitations and desirable performance for clinical use
M. Bidlingmaier (Germany)
- 9:30** Making laboratory medicine results comparable: Understanding the measurements
H. Schimmel (Germany)
- 10:00** Novel mass spectrometry approaches to detect structural variability in clinically useful proteins: Impact on the implementation of reference systems
G. O'Connor (United Kingdom)

Symposium 19**HALL 14.2****CURRENT CHALLENGES IN THE PEDIATRIC LABORATORY**

Chairs: H. Reguengo (Portugal), K. Tomberg (Estonia)

- 9:00** The immature platelet fraction as a novel dynamic cellular parameter for predicting and monitoring the course of neonatal thrombocytopenia
A. Weimann (Germany)
- 9:25** Laboratory markers for differential diagnosis of bacterial and viral infections in children with fever
N. Mayansky (Russia)
- 9:50** Childhood metabolic syndrome: Pathophysiology and laboratory assessment
K. Adeli (Canada)
- 10:15** Diagnostic, prognostic and therapeutic relevance of assay of B-type natriuretic hormone and related peptides in children with congenital heart diseases
M. Cantinotti (Italy)
- 10:40** Pediatric normative data on Abbott, Roche, and Ortho Clinical chemistry systems: Instrument agreement and equivalence determination utilizing pediatric samples
A.A. Venner (Canada)
- 10:50** The use of procalcitonin in early diagnosis
V. Santos (Portugal)

9:00 - 11:00

PARALLEL SESSIONS

Symposium

HALL 7

STANDARDIZATION OF THE PRE-ANALYTICAL PHASE FOR BIOMARKERS

Chairs: G. Lippi (Italy), A.M. Simundic (Croatia)



- 9:00** Standardization and improvement of generic pre-analytical tools and procedures for in-vitro diagnostics
U. Oelmueller (Germany)
- 9:30** Pre-analytical parameters impacting on tissue-based biomarkers
K. Zatloukal (Austria)
- 10:00** Pre-analytical aspects of the Carmague study. Adherence to the AMI and CHF guidelines
P. Laitinen (Finland)
- 10:30** Evidence-based quality guidelines for the pre-analytical phase of blood samples
M. Pazzagli (Italy)

Symposium 20

HALL 4/5

VITAMIN D: MYTH OR MAGIC

Chairs: R. Bais (Australia), V. Palicka (Czech Republic)

- 9:00** Vitamin D requirements for health
H. Bischoff-Ferrari (Switzerland)
- 9:25** A new paradigm for vitamin D activity in bone: Autocrine/paracrine actions
H. Morris (Australia)
- 9:50** Biochemistry and metabolism of vitamin D
G. Jones (Canada)
- 10:15** 25-Hydroxyvitamin D assays - Are they fit for purpose?
G. Carter (United Kingdom)
- 10:40** Vitamin D in problem oriented request panel "vague complaints"
I.C.A. Munnix (The Netherlands)
- 10:50** Abbott Architect 25-OH vitamin D assay compared against LC-MS/MS
J. Bailey (United Kingdom)

9:00 - 11:00

PARALLEL SESSIONS

IFCC-WASPaLM Workshop 10

HALL 9

CHRONIC KIDNEY DISEASE - DEVELOPING A NATIONAL TESTING PROGRAM

Chairs: M. Oellerich (Germany)



- 9:00** A global clinical perspective
F. Alcantara (Brazil)
- 9:30** Why a national program for CKD testing?
D. Seccombe (Canada)
- 10:00** Key factors in successful national CKD programs
G. Jones (Australia)

Workshop 11

HALL 10

9:00-10:30

BIOMARKERS OF ACUTE AND NEURODEGENERATIVE BRAIN DAMAGES

Chairs: J.L. Beaudaux (France)

- 9:00** Diagnosis values of biomarkers for Alzheimer's disease
S. Lehmann (France)
- 9:30** No future for CSF Alzheimer's disease biomarkers without standardization of preanalytical steps
A. Perret-Liaudet (France)
- 10:00** Cerebrospinal fluid biomarkers for the diagnosis/prognosis of neurological diseases
I. Quadrio (France)

11:30-12:45

PLENARY SESSION

HALL 1

NEW AVENUES IN LABORATORY DIAGNOSTICS

Chairs: T. Ozben (Turkey), H. Renz (Germany)

11:30

Development and clinical implementation of next generation sequencing for multi-gene diagnostic panels

K.V Voelkerding (USA)



K.V Voelkerding received his medical degree from the University of Cincinnati College of Medicine in 1983. He subsequently pursued postgraduate training in molecular biology and clinical pathology. From 1990 to 2000, Dr. Voelkerding was a faculty member in the Department of Pathology and Laboratory Medicine at the University of Wisconsin-Madison. Currently, Dr. Voelkerding is an Associate Professor of Pathology at the University of Utah and Medical Director for Advanced Technology and Bioinformatics at the ARUP Laboratories. Dr. Voelkerding's presentation will cover technical and bioinformatic approaches coupled with clinical examples of multi-gene diagnostics.

11:55

Mass Spectrometry: Its future in several disciplines of laboratory medicine

D.F. Hochstrasser (Switzerland)



D.F. Hochstrasser is the chairman of the Genetic & Laboratory Medicine Department of the Geneva University Hospital and Vice Dean of the Faculty of Medicine, University Geneva, Switzerland. He is also Head of the Laboratory Medicine Division of the Geneva University Hospital, Switzerland's largest acute hospital. He still practices as a Board certified physician. At the academic level, he is Full Professor both to Geneva's Department of Structure Biology & Bioinformatics, Medicine Faculty and to the School of Pharmacy, Sciences Faculty. His research focus is on the discovery of clinical biomarkers in brain, pancreas and kidney diseases, on human toxicology and the development of proteomic & clinical chemistry related technologies.

12:20

Proteomics strategies looking into cardiovascular disease.

Disrupted signalling pathways as biomarkers

A. J.R. Heck (The Netherlands)



Since 1998 Albert Heck is Full Professor at Utrecht University at the Science Faculty in the Netherlands. He is scientific director of The Netherlands Proteomics Centre (since 2003) and the Bijvoet Centre for Biomolecular Research (since 2006). In 2001 he was recipient of the Golden Medal of the Dutch Royal Chemical Society. In 2004 he received an honoree Utrecht University "ABC"-professorship and in 2010 he was guest-professor at the ETH Zürich. He has published more than 300 papers in internationally reviewed journals. The Heck laboratory has a track record in proteomics and especially in the analysis of protein post-translational modifications and quantitative proteomics. He introduced and developed TiO₂ as enrichment material for the targeted analysis of phosphopeptides. For quantitative proteomics, the group introduced metabolic stable isotope labeling in multicellular organisms such as *Drosophila* and *C. elegans*, and stable isotope labeling by using chemical approaches. Amongst the broad biomedical interest of the group are embryonic and adult stem cells and chemical proteomics approaches in a cardiovascular context.

13:00 - 14:00

INDUSTRY-SPONSORED WORKSHOPS

HALL 8

ADDING VALUE TO LABORATORY MEDICINE



Chair: G. Beastall (United Kingdom)

- 13:00 Introduction of new program mission
B. Luna (USA)
- 13:20 Good Practices: An example of UK National Pathology Week
S. Jarvis (United Kingdom)
- 13:40 Good Practices: Connecting with Key Stakeholders
G. Beastall (United Kingdom)

HALL 9

LC/MS IN THE CLINICAL LABORATORY - TRANSITION FROM A RESEARCH TOOL TO ROUTINE CLINICAL LABORATORY USE



Chair: K. Khan (United Kingdom)

- 13:00 Implementing LC/MS/MS for therapeutic drug monitoring -
A 10 year review from a routine clinical laboratory perspective
M. Vogeser (Germany)
- 13:30 Experiences of running a routine clinical service for 25-OH vitamin D using a semi-automated LC/MS/MS
L. Perry (United Kingdom)

14:30 - 16:30

PARALLEL SESSIONS

Symposium 21

HALL 1

NEW TECHNOLOGIES IN CLINICAL APPLICATION

Chairs: S. Sandberg (Norway), O. Wagner (Austria)



- 14:30** NMR-spectroscopy in the diagnosis of metabolic diseases
R. Wevers (The Netherlands)
- 14:55** Strategies for protein quantification by integrated elemental and molecular mass spectrometry
Q. Wang (China)
- 15:20** Screening, identifying and quantifying small molecules by hyphenated mass spectrometry in toxicology & drug monitoring
H. Maurer (Germany)
- 15:45** Recent developments in the biology and applications of plasma nucleic acids
D. Lo (China)
- 16:10** Quantification of blood folate forms using stable-isotope dilution ultra performance liquid chromatography tandem mass spectrometry
S.H. Kirsch (Germany)
- 16:20** Lanthanide chelate complementation for highly sensitive protein detection
T. Riuttamäki (Finland)

Symposium 22

HALL 3

INTERTWINING EMERGENCY MEDICINE AND LABORATORY MEDICINE

Chairs: J. Smith (United Kingdom), H. van Pelt (The Netherlands)

- 14:30** Medical emergencies: What is the laboratory's role?
D.S. Young (USA)
- 14:55** What should the clinical laboratory and the toxicologist-pharmacologist offer the poisoned patient?
D.R. A. Uges (The Netherlands)
- 15:20** The clinical laboratory and acts of chemical or biological terrorism...
Can we be prepared?
M. D. Kellogg (USA)
- 15:45** Laboratory resources needed to address unanticipated disasters
C. Kosack (The Netherlands)
- 16:10** Diagnostic and prognostic value of soluble CD14 subtype (sCD14-ST) in emergency patients with early sepsis using the new assay PATHFAST Presepsin
E. Spanuth (Germany)
- 16:20** Usefulness of urinary biomarker NGAL in the management of renal replacement therapy (RRT, hemofiltration)
O. Stanger (Austria)

14:30 - 16:30

PARALLEL SESSIONS

Workshop 12**HALL 8****14:30-16:00**
JOINT SESSION WITH IATDMCT - TRENDS IN THERAPEUTIC DRUG MONITORING: PERSONALIZED IMMUNOSUPPRESSION

Chairs: E. Wieland (Germany)


14:30 TDM of immunosuppressants: Current practice and guidelines
T. van Gelder (The Netherlands)
15:00 Use of endogenous biomarkers to achieve personalized immunosuppression in transplant recipients
M. Oellerich (Germany)
15:30 Impact of pharmacogenetics to optimize immunosuppressive therapy
I. MacPhee (United Kingdom)**Symposium****HALL 7**
TRACEABILITY, STANDARDIZATION, HARMONIZATION: CONCEPTS AND IMPLEMENTATION

Chairs: P. Gillery (France)


14:30 Traceability in laboratory medicine: A review of the international activities
A. Kessler (Germany)
15:00 Standardization versus harmonization
L. Siekmann (Germany)
15:30 Traceability, standardization, harmonization: Concepts and implementation for heterogeneous analytes
L. Thienpont (Belgium)
16:00 Implementation of standardization in clinical practice: Not always an easy task
M. Panteghini (Italy)

14:30 - 16:30

PARALLEL SESSIONS

Workshop 13

HALL 9

14:30-16:00

VITAMIN DEFICIENCY IN ELDERLY PEOPLE: DIAGNOSIS, PREVENTION AND EFFECT ON AGE-RELATED DISEASES

Chairs: W. Hermann (Germany)

14:30 B-Vitamins and neurodegeneration

R. Obeid (Germany)

15:00 Vitamin D and cardiovascular disease: A review of the epidemiological and clinical evidence

R. Scragg (New Zealand)

15:30 Vitamin K and bone health

M.J. Shearer (United Kingdom)

Workshop 14

HALL 10

14:30-16:00

NOVEL INSIGHTS IN IRON METABOLISM: IMPLICATIONS FOR DIAGNOSTIC MEDICINE

Chairs: D.W. Swinkels (The Netherlands)

14:30 Newly identified inherited disorders of iron metabolism

R. Fleming (USA)

15:00 Anemia of chronic disease: Markers for diagnosis and treatment monitoring

G. Weiss (Austria)

15:30 Hepcidin-25, a new biomarker for differentiation of iron-restricted erythropoiesis

L. Thomas (Germany)

16:30 - 17:30

HALL 1

CLOSING CEREMONY

16:30	Congress Presidents <i>Rudolf Tauber, Harald Renz</i>
16:40	Welcome to Milano President of the EuroMedLab Milano 2013 <i>Mauro Panteghini</i>
16:50	Welcome to Istanbul President of the IFCC WorldLab Istanbul 2014 <i>Nazmi Ozer</i>
17:00	Closing remarks IFCC / EFCC / DGKL Presidents <i>Graham Beastall, Rita Horvath, Karl Lackner</i>
17:30	Farewell Istanbul Party



CLOSED MEETINGS

8:00-11:00 Room 47

IFCC TF-PG

Chair: R. van Schaik

8:00-11:00 Room 48

EFCC WG-PEQA

Chair: S. Sandberg

14:30-15:30 Room 48

IFCC WG-cMSP


Chair: S. Lehman

14:30-17:30 Room 47

IFCC TF-CKD

Chair: G. Jones

Visit us at IFCC - EuroMedLab
Hall 15 / Booth 15-01a



«Together, let's build the future»
Hematology & Clinical Chemistry



We invite you to attend our workshop :
TLA - The "Lean" Alternative
Tuesday, May, 17 - 16:45 - 17:45 - Hall 8
Presented by Mick CHOMYN & Martin FOTTLES
(Path Links Pathology - UK)



- Adeli Khosrow** (page 69)
The Hospital for Sick Children, University of Toronto, Canada
khosrow.adeli@sickkids.ca
- Aguzzi Adriano** (page 57)
Institute of Neuropathology, Zurich University, Switzerland
adriano.aguzzi@usz.ch
- Ajzner Eva** (page 64)
University of Debrecen, Debrecen, Hungary
ajzner@gmail.com
- Alcantara Flavio** (page 71)
Central Laboratory Division, Hosp das Clinicas, University of Sao Paulo, Brazil
alcantara@hcnet.usp.br
- Álvarez Menéndez Francisco** (page 25)
Hospital Universitario Central de Asturias, Oviedo, Spain
falvarezmen@gmail.com
- Anderson Leigh** (page 16)
Plasma Proteome Institute, Washington, USA
leighanderson@plasmaproteome.org
- Apple Fred** (page 16)
Hennepin County Medical Center and University of Minnesota, Minneapolis, USA
apple004@umn.edu
- Aufenanger Johannes** (page 27)
Institut für Laboratoriumsmedizin, Klinikum Ingolstadt, Germany
johannes.aufenanger@klinikum-ingolstadt.de
- Bais Renze** (page 40; 70)
Pacific Laboratory Medicine Services Pathology North, Sydney, Australia
rbais@med.usyd.edu.au
- Bartlett Bill** (page 64)
Blood Sciences, Diagnostics Group, Ninewells Hospital and Medical School, NHS Tayside, Dundee, UK
b.bartlett@dundee.ac.uk
- Bauersfeld Walter** (page 18)
Zentrallab, KKH Lörrach, Germany
bauersfeld.walter@klinloe.de
- Beastall Graham H.** (page 19)
Department of Clinical Biochemistry, Macewen Building Royal Infirmary, Glasgow, UK
gbeastall@googlemail.com
- Beaudeau Jean-Louis** (pages 53; 59; 71)
Department of Clinical Biology, Charles Foix Hospital, Paris, France
jean-louis.beaudeau@cfx.aphp.fr
- Becker Stefan** (page 35)
Institut für Virologie, Philipps Universität Marburg, Germany
becker@staff.uni-marburg.de
- Benga Gheorghe** (page 34)
First Laboratory of Genetic Explorations, Cluj-County Clinical Emergency Hospital, Romania
gbenga@umfluj.ro
- Bidlingmaier Martin** (page 69)
Medizinische Klinik Innenstadt, Ludwig-Maximilians University, Munich, Germany
Martin.Bidlingmaier@med.uni-muenchen.de
- Bieber Thomas** (page 55)
Universitäts-Klinikum Bonn, Germany
Thomas.Bieber@ukb.uni-bonn.de
- Bischoff-Ferrari Heike** (page 70)
University of Zurich, Switzerland
Heike.Bischoff@usz.ch
- Blankenberg Stefan** (page 15)
University Medical Center Mainz, Dept. of Medicine II, Germany
stefan.blankenberg@unimedizin-mainz.de
- Blaton Victor** (page 16)
Department of Clinical Chemistry, Brugge, Belgium
victor.blaton@skynet.be
- Blum Hubert** (page 15)
Universitäts-Klinikum Freiburg, Germany
Hubert.blum@uniklinik-freiburg.de
- Boivin Guy** (page 46)
Laval University, Quebec City, Canada
guy.boivin@crchul.ulaval.ca
- Bossuyt Patrick** (page 26)
University of Amsterdam, The Netherlands
p.m.bossuyt@amc.nl
- Boyd Jim** (page 45)
Dept. of Pathology, University of Virginia Health System, Charlottesville, USA
jboyd@virginia.edu
- Brand Angela** (page 37)
Institute for Public Health Genomics CIPHal, Maastricht University, The Netherlands
a.brand@phg.unimaas.nl

- Bruns David** (page 34)
University of Virginia, Charlottesville, USA
dbruns@virginia.edu
- Bunk David** (page 37)
Analytical Chemistry Division, NIST, Gaithersburg, USA
david.bunk@nist.gov
- Cantinotti Massimiliano** (page 69)
Hearth Hospital Massa, National Institute Research, Massa, Italy
massimiliano.cantinotti@ifc.cnr.it
- Carayon Pierre** (page 21; 44)
Marseille Medical School and Mediterranean University Hospital, Marseille, France
pierre.carayon@univmed.fr
- Carter Graham** (page 70)
Charing Cross Hospital, London, UK
b.carter1@which.net
- Casadesus Smith Gemma** (page 53)
Case Western Reserve University, Cleveland, USA
gxc40@case.edu
- Cavalier Etienne** (page 44)
University of Liege, Chu Sart-Tilman, Belgium
Etienne.cavalier@chu.ulg.ac.be
- Ceriello Antonio** (page 35)
Insititut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
Antonio.Ceriello@hotmail.it
- Ceriotti Ferruccio** (pages 15; 21; 53)
Diagnostica & Ricerca, San Raffaele, Milano, Italy
ceriotti.ferruccio@hsr.it
- Choudhury Robin** (page 15)
University of Oxford, Oxford, United Kingdom
robin.choudhury@cardiov.ox.ac.uk
- Christenson Robert** (page 15)
University of Maryland, School of Medicine, Baltimore, USA
rchristenson@umm.edu
- Comabella Manuel** (page 57)
Centre d'Esclerosi Multiple de Catalunya, Hospital Universitari, Barcelona, Spain
mcomabel@vhebron.net
- Croal Bernie** (pages 18; 65)
NHS Grampian, Aberdeen, United Kingdom
bernie.croal@nhs.net
- Cross Anne H.** (page 53)
Washington University School of Medicine, Saint Louis, USA
crossa@neuro.wustl.edu
- Delanghe Joris** (pages 34; 64)
Ghent University Hospital, Ghent, Belgium
joris.delanghe@ugent.be
- Dick Wolfgang** (page 18)
Staedtische Kliniken Neuss Zentrallabor, Neuss, Germany
Wolfgang_Dick@lukasneuss.de
- Domann Eugen** (page 56)
Institut für Medizinische Mikrobiologie, Molekulare Diagnostik, Frankfurt, Germany
eugen.domann@mikrobio.med.uni-giessen.de
- ElGarf Wael** (page 26)
National Research Center, Medical Research Division-Reproductive Health Department, Dokki-Cairo, Egypt
elgarfw@gmail.com
- Ferrari Maurizio** (page 37)
Vita-Salute San Raffaele University, Milan, Italy
Ferrari.maurizio@hsr.it
- Fleming Robert** (page 76)
Saint Louis University, School of Medicine, USA
flemingr@slu.edu
- Frank Elisabeth** (page 68)
Bio Chem Diagnostics Pvt, Mysore, India
anet21frank@yahoo.com
- Freedman Danielle B.** (page 65)
Clinical Biochemistry Luton and Dunstable Hospital, Luton, United Kingdom
Danielle.Freedman@ldh.nhs.uk
- Ganten Detlev** (page 12)
Charité, Universitätsmedizin Berlin, Berlin, Germany
detlev.ganten@charite.de
- Gässler Norbert** (page 18)
Zentrum für Labordiagnostik, Hildesheim, Germany
n.gaessler@bernward-khs.de
- Gay Steffen** (page 25)
Dept. Rheum, University Hospital, Zurich, Switzerland
steffen.gay@usz.ch
- Gerlich Wolfram** (page 15)
Institute for Medical Virology, Justus Liebig University, Giessen, Germany
wolfram.gerlich@viro.med.uni-giessen.de

Gillery Philippe (pages 25; 75)
University Hospital of Reims, France
pgillery@chu-reims.fr

Giroud Claude (page 46)
Bio-Rad, France
Claude.Giroud@bio-rad.com

Goldsmith Barbara (page 44)
Clinical and Laboratory Standards Institute (CLSI),
Pennsylvania, Wayne, USA
bgoldsmith@clsi.org

Gouget Bernard (page 15; 58)
Fédération Hospitalière de France, Paris, France
b.gouget@fhf.fr

Greenberg Neil (page 17)
Clinical Laboratory Products, Ortho-Clinical
Diagnostics, Inc., Rochester, NY, USA
ngreenbe@ocdus.jnj.com

Griesmacher Andrea (page 27)
Centre Institute of Medical and Chemical
Laboratory Diagnostics, University Hospital of
Innsbruck, Austria
andrea.griesmacher@uki.at

Gronowski Ann (page 25)
Washington University School of Medicine, St.
Louis, Missouri, USA
gronowski@wustl.edu

Grubb Anders (page 17)
Department of Clinical Chemistry, University
Hospital, Lund, Sweden
anders.grubb@med.lu.se

Haferlach Torsten (page 63)
MLL Munich Leukemia Laboratory, Munich, Germany
Torsten.haferlach@mll.com

Haining W. Nicholas (page 38)
Dana-Farber Cancer Institute, Harvard Medical
School, Boston, USA
nicholas_haining@dfci.harvard.edu

Hallaj Zuhair (page 26)
World Health Organization, Cairo, Egypt
hallajz@emro.who.int

Hallworth Michael (page 65)
Dept. Clinical Biochemistry, Royal Shrewsbury
Hospital, Shrewsbury, United Kingdom
mike.hallworth@sath.nhs.uk

Harb Fouad (page 68)
Arab Fed. of Clinical Chemistry, Damascus, Syria
fouad.harb@scs-net.org

Harmsen Dag (page 35)
University Munster, Germany
dag.harmsen@ukmuenster.de

Haushofer Alexander (page 27)
Hospital St. Poelten, St. Poelten, Austria
Alexander.Haushofer@stpoelten.lknoe.at

Heck Albert J.R. (page 72)
Utrecht University, Biomolecular Mass
Spectrometry and Proteomics Group,
The Netherlands
a.j.r.heck@chem.uu.nl

Helsens Kenny (page 56)
Computational Omics and Systems Biology Group,
Department of Medical Protein Research, Universiteit
Gent, Belgium
kenny.helsens@ugent.be

Heneghan Carl (page 26)
Dept. of Primary Health Care and Directory Centre
for Evidence-Based Medicine, Oxford,
United Kingdom
carl.heneghan@dphpc.ox.ac.uk

Herrmann Wolfgang (page 40; 76)
Medical School, Saarland University, Homburg,
Germany
w-herrmann@gmx.de

Hicks Jocelyn J.M. (page 54)
George Washington University Medical Center,
Washington, USA
hicksjmb@gmail.com

Hiemke Christoph (page 34)
Department of Psychiatry and Psychotherapy,
University Medical Center, Mainz, Germany
hiemke@mail.uni-mainz.de

Hochstrasser Denis F. (page 72)
Hopitaux universitaires de Genève, Switzerland
denis.hochstrasser@unige.ch

Holick Michael F. (page 34)
Boston University Medical Center, Boston, USA
mfholick@bu.edu; lorrie@bu.edu

Hong Shang (page 66)
First Hospital, China Medical University,
Shenyang, China
hongshang100@hotmail.com

Hoppe Berthold (page 58)
Institute of Transfusion Medicine, Campus
Virchow Klinikum, Charité Universitätsmedizin
Berlin, Germany
berthold.hoppe@charite.de

Hornemann Thorsten (page 65)
Inst. für Klinische Chemie, Zurich, Switzerland
thorsten.hornemann@usz.ch

Horvath Andrea Rita (pages 26; 38; 65)
Seals Department Clinical Chemistry, Prince of
Wales Hospital, Sydney, Australia
rita.horvath@sesiahs.health.nsw.gov.au

Huber Andreas R. (pages 27; 36)
Kantonsspital, Aarau, Switzerland
andreas.huber@ksa.ch

Hubmann Michael (page 45)
Medizinisches Zentrallaboratorium, Feldkirch,
Austria
mhubmann@mzl.at

Huestis Marilyn (page 16)
National Institute on Drug Abuse, Baltimore, USA
mhuestis@intra.nida.nih.gov

Huisman Wim (page 46)
Clinical Chemistry Laboratory, Medical Center
Haaglanden, Den Haag, The Netherlands
w.huisman@mchaaglanden.nl

Ichihara Kiyoshi (page 45; 59)
Yamaguchi University Graduate School of
Medicine, Faculty of Health Sciences, Ube, Japan
ichihara@yamaguchi-u.ac.jp

Isermann Berend (page 65)
Universitätsklinikum Heidelberg, Heidelberg,
Germany
Berend.Isermann@med.uni-heidelberg.de

Jacobs Ellis (page 17)
New York University, School of Medicine, USA
Ellis.Jacobs@nyumc.org

Jansen Rob (page 46)
SKML, Nijmegen, The Netherlands
rjansen@skml.nl

John W. Garry (page 25)
Clinical Biochemistry Norfolk and Norwich
University Hospital, Norwich, United Kingdom
g.john@nnuh.nhs.uk

Jones Graham (pages 17; 71)
St Vincents Hospital, Sydney, Australia
gjones@stvincents.com.au

Jones Glenville (page 70)
Department of Biochemistry Queen's University,
Kingston, Canada
gj1@queensu.ca

Kaminski Wolfgang (page 65)
Institute for Clinical Chemistry, University of
Hedelberg, Mannheim, Germany
Wolfgang.Kaminski@umm.de

Kappelmayer Janos (page 63)
University of Debrecen, Hungary
kappelmayer@med.unideb.hu

Kappert Kai (page 21)
Zentralinstitut für Laboratoriumsmedizin
Charité, Berlin, Germany
kai.kappert@charite.de

Katus Hugo A. (page 37)
University Hospital Heidelberg Internal Medicine,
Internal III Cardiology, Germany
Hugo.Katus@med.uni-heidelberg.de

Keith W. Nicol (page 19)
Institute of Cancer Sciences, Glasgow University,
United Kingdom
n.keith@beatson.gla.ac.uk

Kellogg Mark D. (page 74)
Children's Hospital Boston, USA
mark.kellogg@childrens.harvard.edu

Kelso Anne (page 46)
WHO Collaborating Centre for Reference and
Research on Influenza, North Melbourne, Australia
anne.kelso@influenzacentre.org

Kessler Anja (page 75)
Reference Institute of Bioanalytics, Bonn,
Germany
anja.kessler@uni-bonn.de

Kessler Harald (page 68)
Medical University of Graz, Graz, Austria
harald.kessler@medunigraz.at

Khalil El Taher (page 26)
Institute of Endemic Diseases, Medical Sciences
Campus, Khartoum, Sudan
eltahirk@iend.org

Kiehntopf Michael (page 20; 37; 39)
Institut für Klinische Chemie und
Laboratoriumsdiagnostik, Jena, Germany
michael.kiehntopf@med.uni-jena.de

Kilpatrick Eric S. (pages 18; 65)
Dept. of Clinical Biochemistry, Hull Royal Infirmary,
United Kingdom
Eric.Kilpatrick@hey.nhs.uk

- King May-Jean** (page 36)
International Blood Group Reference Laboratory,
NHS Blood & Transplant, Bristol, UK
may-jean.king@nhsbt.nhs.uk
- Klakow-Franck Regina** (page 27)
Bundesärztekammer, Berlin, Germany
Regina.Klakow-Franck@baek.de
- Klouche Mariam** (pages 17; 44)
Laborzentrum Bremen, Germany
mariam.klouche@laborzentrum-bremen.de
- Knabbe Cornelius** (page 21; 39)
Institut für Laboratoriums- und Transfusionsmedizin,
Universitätsklinik der Ruhr, Bad Oeynhausen,
Germany
cknabbe@hdz-nrw.de
- Kocna Petr** (page 17)
Charles University, Prague, Czech Republic
kocna@lf1.cuni.cz
- Kohlmann Alexander** (page 68)
MLL Munich Leukemia Laboratory, Munich, Germany
alexander.kohlmann@mll.com
- Kohse Klaus** (page 54; 59)
Klinikum Oldenburg, Germany
Kohse.Klaus@klinikum-oldenburg.de
- Koike Takao** (page 25)
Depart. of Medicine II, Hokkaido University
Graduated School of Medicine, Sapporo, Japan
tkoike@med.hokudai.ac.jp
- Kosack Cara** (page 74)
Medicins sans frontieres, Amsterdam,
The Netherlands
cara.kosack@amsterdam.msf.org
- Kubista Mikael** (page 68)
Tataa Biocenter, Gothenburg, Sweden
mikael.kubista@tataa.com
- Kulasingam Vathany** (page 16)
University Health Network and University of
Toronto, Toronto, Canada
vathany.kulasingam@uhn.on.ca
- Lackner Karl** (pages 19; 36; 65)
Institute of Clinical Chemistry and Laboratory
Medicine, Medical Center of the J.G. University,
Mainz, Germany
karl.lackner@unimedizin-mainz.de
- Laitinen Päivi** (page 70)
Laboratory, Central Ostrobothin Hospital District,
Kokkola, Finland
paivi.laitinen@oulu.fi
- Lam Christopher W.K** (page 55)
Macau Institute for Applied Research in Medicine
and Health, Taipa, Macau
wklam@must.edu.mo
- Lämmle Bernhard** (pages 27; 63)
Universitätsklinik für Haematologie, Inselspital,
Bern, Switzerland
bernhard.laemmle@insel.ch
- Langlois Michel** (page 64)
Dept. Laboratory Medicine, Az. St. Jan Hospital,
Bruges, Belgium
michel.langlois@azsintjan.be
- Le Roux Carel** (page 44)
Imperial College London, United Kingdom
c.leroux@imperial.ac.uk
- Lehmann Sylvain** (page 71)
Hopital St. Eloi-Biochimie, Montpellier, France
s-lehmann@chu-montpellier.fr
- Libeer Jean-Claude** (page 46)
EFCC Quality Management Committee, Belgium
jclibeer@skynet.be
- Lichtinghagen Ralf** (page 18; 21)
Hannover Medical School, Institute of Clinical
Chemistry, Hannover, Germany
lichtinghagen.ralf@mh-hannover.de
- Linder Mark** (page 34)
University of Louisville, School of Medicine,
Louisville, USA
mwlind01@gwise.louisville.edu
- Lippi Giuseppe** (page 53; 70)
U.O. Diagnostica Ematochimica, Azienda
Ospedaliero-Universitaria di Parma, Italy
giuseppe.lippi@univr.it
- Little Randie** (page 18)
University of Missouri, School of Medicine,
Columbia, USA
littler@health.missouri.edu
- Lo Dennis** (pages 16; 74)
The Chinese University of Hong Kong, China
loym@cuhk.edu.hk
- Lopez Joseph** (page 39; 55)
Mahsa University, Petaling Jaya, Malaysia
jblopez@streamyx.com
- Lyon Andrew** (page 17)
University of Calgary & Calgary, Lab. Services,
Canada
andrew.lyon@cls.ab.ca

- Macdonald Rainer** (page 45)
Physikalisch-Technische Bundesanstalt (PTB),
Berlin, Germany
Rainer.Macdonald@ptb.de
- MacPhee Iain** (page 75)
St. George's, University of London, London, UK
imacphee@sghms.ac.uk
- Majkic-Singh Nada** (page 63)
Institute of Medical Biochemistry, Clinical Center of
Serbia, Belgrade, Serbia
singh@eunet.rs; dmbj@eunet.rs
- Mannhalter Christine** (page 68)
Medical University Vienna, Dept. Laboratory
Medicine, Vienna, Austria
christine.mannhalter@meduniwien.ac.at
- Martins Ralph N.** (pages 53; 57)
Ageing and Alzheimers, Edith Cowan University,
Perth, Australia
r.martins@ecu.edu.au
- Maurer Hans** (page 74)
Department of Experimental and Clinical Toxicology,
Saarland University, Homburg, Germany
hans.maurer@uks.eu
- Mayansky Nikolay** (page 69)
Scientific Center for Children's Health, Moscow,
Russia
mayansky@nczd.ru
- Meyer Helmut E.** (page 56)
Ruhr-University of Bochum, Recklinghausen,
Germany
helmut.e.meyer@rub.de
- Migliarino Gabriel** (page 68)
GMigliarino Consultores, Buenos Aires, Argentina
gmigliarino@gmigliarino.com
- Moraes Figueiredo Luiz Tadeu** (page 56)
University of Sao Paulo, Ribeirao Preto, Brazil
ltmfigue@fmrp.usp.br
- Morris Howard** (page 70)
University of South Australia, Adelaide, Australia
howard.morris@health.sa.gov.au
- Muckenthaler Martina** (page 36)
Paediatric Oncology, Haematology and
Immunology University of Heidelberg, Germany
Martina.Muckenthaler@med.uni-heidelberg.de
- Müller Christian** (page 15)
Univeritätsspital Basel, Switzerland
chmueller@uhbs.ch
- Müller Mathias M.** (page 38)
Austrian Society of Quality Assurance and
Standardisation, Wien, Austria
mathias.mueller1@chello.at
- Müller Michael** (page 27)
BDL C.V. Oldenburg, Germany
m.mueller@medlab-oldenburg.de
- Muszbek László** (page 63)
University of Debrecen, Medical and Health
Science Center, Debrecen, Hungary
muszbek@med.unideb.hu
- Neubauer Andreas** (page 63)
Universitätsklinik für Hematologie, Onkologie,
Immunologia, Marburg, Germany
neubauer@staff.uni-marburg.de
- Neumaier Michael** (pages 16; 37)
University Medicine Mannheim, Mannheim, Germany
michael.neumaier@medma.uni-heidelberg.de
- Neurath Markus F.** (page 38)
Department of Medicine 1, University Hospital
Erlangen, Germany
markus.neurath@uk-erlangen.de
- Obeid Rima** (page 76)
Department of Clinical Chemistry Central Laboratory,
University of Saarland, Homburg, Germany
rima.obeid@uniklinikum-saarland.de
- O'Connor Gavin** (page 69)
Principal Scientist, Mass Spectrometry
LGC, United Kingdom
GOC@lgc.co.uk
- Oellerich Michael** (pages 71; 75)
Chemistry, George-August-University, Göttingen,
Germany
moeller@med.uni-goettingen.de
- Oelmueller Uwe** (page 70)
Qiagen GmbH, Hilden, Germany
Uwe.Oelmueller@qiagen.com
- Ogriseg Martin** (page 45)
Lab. of Clinical Pathology, Ospital of Brixen, Italy
martin.ogriseg@sb-brixen.it
- Oldenburg Johannes** (page 54)
Institute of Experimental Haematology
and Transfusion Medicine, University Clinic Bonn,
Germany
johannes.oldenburg@ukb.uni-bonn.de
- Oosterhuis Wytze** (page 64)
Atrium Medical Center, Heerlen, The Netherlands
w.oosterhuis@atriummc.nl

Oudejans Cees (page 54; 59)
VU University Medical Center, Amsterdam,
The Netherlands
cbm.oudejans@vumc.nl

Ozben Tomris (page 72)
Akdeniz University, Medical Faculty, Antalya, Turkey
tomris.ozben@unimore.it

Ozer Nazmi (page 17; 58)
Hacettepe University, Faculty of Medicine,
Department of Biochemistry, Sıhhiye-Ankara,
Turkey
nozertbd@gmail.com

Palicka Vladimir (page 70)
Charles University, Prague, Czech Republic
palicka@lfhk.cuni.cz

Panteghini Mauro (pages 45; 75)
University of Milan, Milan, Italy
mauro.panteghini@unimi.it

Pantel Klaus (page 16)
Universitätsklinikum Hamburg, Hamburg, Germany
pantel@uke.uni-hamburg.de

Parkes Helen (page 69)
LGC LTD, Teddington, United Kingdom
helen.parkes@lgc.co.uk

Payne Deborah (page 55)
American Pathology Partners - Unipath LLC,
Denver, USA
dpayne@unipathllc.com

Pazzagli Mario (pages 55; 70)
University of Florence, Italy
m.pazzagli@dfc.unifi.it

Perret-Liaudet Armand (page 71)
Hospices Civils de Lyon, France
armand.perret-liaudet@chu-lyon.fr

Perschel Frank Holger (pages 40; 58)
Charité, Universitätsmedizin, Berlin, Germany
frank.perschel@charite.de

Picheth Geraldo (page 64)
Federal University of Parana, Department of
Medical Pathology, Curitiba, Brazil
gpicheth@ufpr.br

Pilonetto Marcelo (page 46)
Brazilian Society of Clinical Analysis, Brazil
m.pilonetto@pucpr.br

Pirmohamed Munir (pages 34; 54)
University of Liverpool, United Kingdom
munirp@liverpool.ac.uk

Platts-Mills Thomas A. E. (page 55)
University of Virginia Health system,
Charlottesville, USA
tap2Z@virginia.edu

Plebani Mario (pages 53; 64)
University of Padova, Italy
mario.plebani@unipd.it

Polack Fernando P. (page 46)
Vanderbilt University, Nashville, USA
Malinez@infant.org.ar

Preissner Klaus T. (page 27)
Justus Liebig Universität Medical School,
Department Biochemistry, Giessen, Germany
Klaus.T.Preissner@biochemie.med.uni-giessen.de

Prinz Nadine (page 65)
Institute of Clinical Chemistry and Laboratory
Medicine, University Medical Centre Mainz,
Germany
Nad.Prinz@web.de

Psarra Katherina (page 40; 68)
Evangelismis Hospital, Athens, Greece
stcps@hol.gr; info@eekx-kb.gr

Pulkki Kari (page 44; 59)
Clinical Chemistry, University of Eastern Finland,
Kuopio, Finland
kari.pulkki@islab.fi

Quadrio Isabelle (page 71)
Service de Neurobiologie, Centre de Biologie Est,
Hospices Civils de Lyon, France
isabelle.quadrio@chu-lyon.fr

Raabe-Meyer Gisela (page 18)
Praxis für Humangenetik, Hannover, Germany
grm@humangenetik-hannover.de

Ratzu Vlad (page 15)
University Pierre et Marie Curie, Paris, France
vratziu@teaser.fr

Raue Friedhelm (page 44)
Endocrine Practice, Heidelberg, Germany
friedhelm.raue@raue-endokrinologie.de

Reaman Gregory H. (page 19)
The George Washington University, USA
greaman@cnmc.org

Reguengo Henrique (page 69)
Centro Hospitalar do Porto, Portugal
hlreguengo@gmail.com

Renz Harald (pages 38; 72)
Institute of Laboratory Medicine and
Pathobiochemistry, Molecular Diagnostics Philipps
University Marburg, Germany
renzh@med.uni-marburg.de

Rifai Nader (pages 16; 64)
Children's Hospital, Boston, USA
Nader.Rifai@tch.harvard.edu

Rogic Dunja (pages 44; 64)
Clinical Institute for Laboratory Diagnostics,
University Hospital Zagreb, Croatia
dunjarogic@hotmail.com

Ronco Claudio (pages 17; 34)
Department of Nephrology, Dialysis and renal
transplantation, St. Bortolo Hospital, Vicenza, Italy
cronco@goldnet.it

Rosendaal Frits R. (page 63)
Leiden University Medical Ctr, Dept. Clinical
Epidemiology, The Netherlands
f.r.rosendaal@lumc.nl

Rosengren Anders (page 25)
Lund University Diabetes Centre, Dep. Clinical
Sciences Malmö, Sweden
Anders.Rosengren@med.lu.se

Rousseau Francois (page 55)
Faculté de Médecine, Université Laval & Chuq,
Québec, Canada
Francois.Rousseau@mac.com

Rueda Jesus (page 26)
European Diagnostic Manufacturers Association
(EDMA), Brussels, Belgium
j.rueda@edma-ivd.be

Rydén Ingvar (page 51)
Swedish Society of Clinical Chemistry, Sweden
Ingvar.Ryden@ltkalmar.se

Sack Ulrich (pages 20; 25)
TRM Leipzig, Germany
Ulrich.Sack@medizin.uni-leipzig.de

Sacks David (page 25)
National Institutes of Health, Bethesda, Maryland,
USA
sacksdb@mail.nih.gov

Samuelsson Ola (page 17)
Department of Nephrology, Sahlgrenska University
Hospital, Goteborg, Germany
ola.samuelsson@vgregion.se

Sandberg Sverre (page 64; 74)
Laboratory of Clinical Biochemistry, Haukeland
University Hospital, Bergen, Norway
sverre.sandberg@isf.uib.no

Schimmel Heinz (page 69)
European Commission, Joint Research Centre,
Geel, Belgium
Heinz.Schimmel@ec.europa.eu

Schleicher Erwin (page 25)
University Clinic Tübingen, Clinical Chemistry,
Tübingen, Germany
erwin.schleicher@med.uni-tuebingen.de

Schmitz Gerd (page 56)
University Hospital Regensburg, Institute for
Clinical Chemistry and Laboratory Medicine,
Germany
gerd.schmitz@klinik.uni-regensburg.de

Schuff-Werner Peter (page 63)
Institute of Clinical Chemistry and Laboratory
Medicine, University of Rostock, Germany
pschuffw@med.uni-rostock.de

Scragg Robert (page 76)
School of Population Health, University S.
Auckland, New Zealand
r.scragg@auckland.ac.nz

Seccombe David (page 71)
Canadian External Quality Assessment Laboratory
(CEQAL), Vancouver, Canada
dseccombe@ceqal.com

Shannan Ghassan (pages 26; 68)
Syrian Clinical Laboratory Association, Damascus,
Syria
ghassanshannan@gmail.com

Shearer Martin J. (page 76)
GSTS Pathology, St. Thomas' Hospital, Londo,
United Kingdom
Martin.Shearer@gsts.com

Sheldon Joanna (page 25)
St. George's Hospital, London, United Kingdom
jsheldon@sgul.ac.uk

Sidransky David (page 16)
Johns Hopkins School of Medicine Director,
Otolaryngology-Head and Neck Cancer
Research, Baltimore, USA
dsidrans@jhmi.edu

Siekmann Lothar (page 75)
University of Bonn, Germany
lothar.siekmann@ukb.uni-bonn.de

Sierra Amor Rosa (page 21; 36)
Veracruz, Ver, Mexico
rsierramor@hotmail.com

Simundic Ana-Maria (page 70)
Clinical Institute of Chemistry, University Hospital
"Sestre Milosrdnice", Zagreb, Croatia
am.simundic@gmail.com

Sinha Pranav (page 21; 40)
IMCL, LKH-Klagenfurt, Austria
psinha@gmx.net

Skrha Jan (page 35)
3rd Dept. of Internal Medicine and Laboratory for
Endocrinology & Metabolism, 1st Faculty of
Medicine, Prague, Czech Republic
jan.skrha@lf1.cuni.cz

Smith Janet (page 74)
Chair IFCC Education and Management Division,
Birmingham, United Kingdom
janmsmith@Talk21.com

Smolen Josef S. (page 25)
Medical University of Vienna, Hietzing Hospital
Vienna, Austria
josef.smolen@wienkav.at

Sprongl Ludek (page 46)
Central Laboratory, Sumpers Hospital,
Czech Republic
sprongl@nemspk.cz

Steenkamp Vanessa (page 68)
University of Pretoria, South Africa
vanessa.steenkamp@up.ac.za

Stenman Ulf-Hakan (page 16)
Dept. of Clinica Chemistry, Helsinki University,
Finland
ulf-hakan.stenman@hus.fi

StJohn Andrew (page 26)
Ortho Clinical Diagnostics, Asia Pacific, Australia
ASTJOHN@its.inj.com

Stowasser Michael (page 44)
Endocrine Hypertension Research Centre, University
of Queensland, Princess Alexandra Hospital,
Brisbane, Australia
m.stowasser@uq.edu.au

Suerbaum Sebastian (page 35)
Institute of Medical Microbiology and Hospital
Epidemiology, Hannover Medical School,
Germany
suerbaum.sebastian@mh-hannover.de

Swinkels Dorine W. (pages 36; 76)
Department of Laboratory Medicine, Radboud
University Nymegen, The Netherlands
D.Swinkels@labgk.umcn.nl

Sypniewska Grazyna (page 40; 53)
Dept. of Laboratory Medicine, Collegium Medicum
Nicolaus Copernicus University, Bydgoszcz, Poland
grazynaodes@interia.pl

Szekeres Thomas (page 54)
Clinical Institute for Laboratory Medicine, Wien,
Austria
thomas.szekeres@meduniwien.ac.at

Tate Jill (page 37; 58)
Chemical Pathology Dept., Pathology
Queensland, Royal Brisbane and Womens'
Hospital, Australia
jill_tate@health.qld.gov.au

Tauber Rudolf (pages 35; 57)
Zentralinstitut für Laboratoriumsmedizin
Charité Universitätsmedizin Berlin, Berlin, Germany
Rudolf.Tauber@charite.de

Tavora Mira Marcelo (page 56)
Graduate Program in Health Sciences, PUCPR,
Curitiba, Brazil
m.mira@pucpr.br

Thienpont Linda (pages 44; 75)
Laboratory for Analytical Chemistry, Fac. Pharm.
Sci, Ghent University, Belgium
linda.thienpont@ugent.be

Thiery Joachim (pages 36; 65)
Institut für Laboratoriumsmedizin, Leipzig, Germany
thiery@medizin.uni-leipzig.de

Thomas Lothar (page 39; 76)
Krankenhaus Nordwest, Frankfurt, Germany
th-books@t-online.de

Thornalley Paul J. (page 35)
University of Warwick, Coventry, United Kingdom
P.J.Thornalley@warwick.ac.uk

Tomberg Karel (page 59; 69)
North Estonia Medical Centre, Tallinn, Estonia
karel.tomberg@regionaalhaigla.ee

Tuma Ulisses (page 34)
Laboratory Moderno Ltda, Goiania, Brazil
ultuma@terra.com.br

Uges Donald R.A. (page 74)
University Medical Center Groningen,
The Netherlands
d.r.a.uges@apoth.umcg.nl

- Valenta Rudolf** (page 55)
 Medical University of Vienna, Austria
rudolf.valenta@meduniwien.ac.at
- van den Boom Dirk** (page 54)
 Research & Development Sugunam, Inc. 3595
 John Hopkins Court, San Diego, USA
dvandenboom@sequenom.com
- van Gelder Teunis** (page 75)
 Erasmus Medical Center Rotterdam,
 The Netherlands
t.vangelder@erasmusmc.nl
- van Pelt Hans** (page 20; 74)
 U. Diagnostics, Utrecht, The Netherlands
f2hjpgelt@hetnet.nl
- van Schaik Ron** (pages 34; 55)
 Dept. Clinical Chemistry, Erasmus University
 Medical Center, Rotterdam, The Netherlands
r.vanschaik@erasmusmc.nl
- Vaubourdolle Michel** (page 15)
 Pole de Biologie-Imagine, AP HP, Paris, France
michel.vaubourdolle@sat.aphp.fr
- Vissa Varalakshmi** (page 56)
 Colorado State University, Fort Collins, USA
Varalakshmi.Vissa@ColoState.edu
- Voelkerding Karl V.** (page 72)
 ARUP Laboratories, University of Utah, USA
voelkek@aruplab.com
- Vogt Wolfgang** (page 45)
 Munich, Germany
wolfgang.vogt148@superkabel.de
- von Eckardstein Arnold** (page 15; 20)
 UniversitätsSpital Zürich, Switzerland
arnold.voneckardstein@usz.ch
- Wagener Christoph** (pages 19; 20; 56)
 Dept. of Clinical Chemistry, University Medical
 Center Hamburg-Eppendorf, Hamburg, Germany
wagener@uke.uni-hamburg.de
- Wagner Oswald** (page 59; 74)
 University of Wien, Austria
oswald.wagner@meduniwien.ac.at
- Wald Nicholas** (page 54)
 Wolfson Institute of Preventive Medicine, London,
 United Kingdom
n.j.wald@qmul.ac.uk
- Walter Michael** (pages 39; 58)
 Zentralinstitut für Laboratoriumsmedizin und
 Pathobiochemie, Charité, Berlin, Germany
M.Walter@charite.de
- Walter Ulrich** (pages 36; 39; 63)
 Zentrum Innere Medizin, Universitätsklinikum
 Würzburg, Germany
uwalter@klin-biochem.uni-wuerzburg.de
- Wang Qiuquan** (page 74)
 Department of Chemistry & the Key Lab of
 Analytical Sciences, College of Chemistry and
 Chemical Engineering, Xiamen University, China
qqwang@xmu.edu.cn
- Watson Ian** (page 44)
 Aintree University Hospital NHS Foundation Trust,
 Liverpool, United Kingdom
IAN.WATSON@aintree.nhs.uk
- Weck Karen** (page 54)
 University of North Carolina, Chapel Hill, USA
KWeck@unch.unc.edu
- Weigel Günter** (page 27)
 Innsbruck Medical University, Inst. for Medicine
 and Chem., Austria
guenter.weigel@uki.at
- Weimann Andreas** (page 69)
 Central Institute of Laboratory Medicine, Charité
 University Medical Center, Berlin, Germany
andreas.weimann@charite.de
- Weiss Gunter** (page 76)
 Dept. of Internal Medicine, Clinical Immunology
 and Infectious Diseases, Innsbruck, Austria
guenter.weiss@i-med.ac.at
- Werfel Thomas** (page 55)
 Hannover Medical School, Hannover, Germany
werfel.thomas@mh-hannover.de
- Wesenberg James** (page 36)
 Alberta Health Services Red Deer Regional
 Hospital Centre, Canada
jwesenberg@dthr.ab.ca
- Westermann Jörg** (page 63)
 Charité Universitäts-mezizin Berlin, Germany
joerg.westermann@charite.de
- Westgard James** (page 53)
 University of Wisconsin, Madison, USA
James@westgard.com

Wevers Ron (page 74)
 Laboratory Genetic Endocrine and Metabolic Diseases, Dept. Laboratory Medicine, Univ. Medical Centre Nymegen, The Netherlands
r.wevers@labgk.umcn.nl

Weykamp Cas W. (page 18)
 Queen Beatrix Hospital, Winterswijk, The Netherlands
C.W.Weykamp@skbwinterswijk.nl

Whiteley William (page 53)
 MRC Clinician Scientist, University of Edinburgh, United Kingdom
william.whiteley@ed.ac.uk

Wiegel Bernhard (pages 27; 45)
 German Society for Clinical Chemistry and Laboratory Medicine, Working Group on Laboratory Management, Germany
dr.bernhard.wiegel@t-online.de

Wieland Eberhard (page 40; 59; 75)
 Klinikum Stuttgart, Center for Clinical Pathology, Pharmacy and Hygiene, Germany
e.wieland@klinikum-stuttgart.de

Witte Wolfgang (page 35)
 Robert Koch Institute, Wernigerode Branch, Germany
wittew@rki.de

Wittwer Carl T. (page 68)
 University of Utah, Salt Lake City, USA
carl.wittwer@path.utah.edu

Wyer Lou Ann (page 44)
 Sentara Healthcare, Norfolk, USA
lawyer@sentara.com

Young Ian (pages 15; 55; 57)
 Centre for Public Health, Queen's University Belfast, United Kingdom
i.young@qub.ac.uk

Young Donald S. (page 74)
 University of Pennsylvania, Philadelphia, USA
donaldyo@mail.med.upenn.edu


Zahedi Rene (page 56)
 Leibniz, Institut für Analytische, Wissenschaften - ISAS - Dortmund, Germany
rene.zahedi@isas.de

Zatloukal Kurt (page 70)
 Institute of Pathology, Medical University of Graz, Austria
kurt.zatloukal@medunigraz.at

Zerah Simone (page 46)
 Laboratory Zerah-Taar-Pfeffer, Paris, France
simone.zerah@wanadoo.fr

Zima Tomas (pages 16; 20; 35; 54)
 First Faculty of Medicine, Prague, Czech Republic
zimatom@cesnet.cz

Zinder Oren (page 63)
 Laboratory Medicine, Faculty of Medicine, the Technion, Israel Institute of Technology, Haifa, Israel
ozinder@matav.net.il



Solutions that drive knowledge

Life changing knowledge begins in the laboratory. At Ortho Clinical Diagnostics, we are leading efficiency and productivity through innovative technology and high quality services that help you provide the highest level of care for your patients.

Join us at
booth 17-10
to learn more

Plan to attend the industry-sponsored workshops from Ortho Clinical Diagnostics:

16 MAY | 13:00-14:00 | HALL 8

Testing for Vitamin D Deficiency:
Defining At-Risk Populations

ISW 1

16 MAY | 15:30-16:30 | HALL 14.2

ENHANCING PATIENT CARE IN THE CHALLENGING DIAGNOSTIC ARENA IN EUROPE: How to Face European Healthcare and Diagnostics Challenges with Process Solutions that Maximize Clinical Laboratory Cost Efficiencies

ISW 9

17 MAY | 13:00-14:00 | HALL 10

ENHANCING PATIENT CARE IN THE CHALLENGING DIAGNOSTIC ARENA IN EUROPE: Innovative Technological Platforms and High Quality Services to Enhance Productivity in Increasingly Complex Lab Structures

ISW 23

Ortho Clinical Diagnostics
a *Johnson & Johnson* company



QUALITY CONTROL NEEDS TO BE AS PRECISE AND ACCURATE AS CLOCKWORK.
GUARANTEE THE ACCURACY AND PRECISION OF YOUR TEST RESULTS
WITH RANDOX



The extensive Acusera range of Quality Controls and Calibrators covers over 300 routine and specialized parameters. In addition to this our diverse product range guarantees excellent choice, stability and consolidation. With nearly 30 years experience in the diagnostics industry, Randox understands the importance of laboratory quality, so every control we manufacture is to the highest standard.

- Third party controls offering unbiased assessment of performance
- Most accurate target values based on results from over 16,000 independent laboratories
- Most consistent material, with minimal variation between lots
- Most stable material, Randox controls will meet and often exceed their stability claims
- Highest quality material with no added preservatives or stabilizers
- 100% human material will not interfere with antibody based tests

**PLEASE VISIT US
ON STAND 15.01
HALL 15**

Controls Available

- Clinical Chemistry • Immunoassay • Immunology/Proteins • Cardiac • Lipids
- Diabetes • Urine Chemistry • Urinalysis • Toxicology • Therapeutic Drugs
- Tumor Markers • Maternal Screening • Coagulation • Blood Gas
- Speciality/Research • Antioxidants



Set the standard for good quality control practice with Randox Acusera

RANDOX

Randox Laboratories Limited

55 Diamond Road, Crumlin, County Antrim, BT29 4QY, United Kingdom

T +44 (0) 28 9442 2413 **F** +44 (0) 28 9445 2912 **E**

marketing@randox.com | www.randox.com

